

CITATION REPORT

List of articles citing

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?

DOI: 10.3233/jad-2005-7107

Journal of Alzheimer's Disease, 2005, 7, 63-80.

Source: <https://exaly.com/paper-pdf/37943016/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1342	Insulin signaling, diabetes mellitus and risk of Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2005 , 7, 81-4	4.3	39
1341	Posttranslational modification of lipoproteins--a fatal attraction in metabolic disease?. <i>Journal of Alzheimer's Disease</i> , 2005 , 7, 315-7	4.3	7
1340	Inflammation, atherosclerosis, and aspects of insulin action. 2005 , 28, 2312-9		43
1339	Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. 2005 , 54, 3343-8		109
1338	Imaging on the binding of FITC-insulin with insulin receptors in cortical neurons of rat. 2005 , 2005, 5706-8		
1337	Lipid-protein interactions of growth factor receptor-bound protein 14 in insulin receptor signaling. 2005 , 44, 15461-71		13
1336	Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. 2006 , 199, 265-73		246
1335	Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. 2006 , 79, 2209-16		112
1334	Insulin signaling in the central nervous system: learning to survive. 2006 , 79, 205-21		322
1333	Correlations of disability and biologic alterations in Alzheimer brain and test of significance by a therapeutic trial in humans. <i>Journal of Alzheimer's Disease</i> , 2006 , 9, 207-18	4.3	14
1332	Early developmental expression of two insulins in zebrafish (<i>Danio rerio</i>). 2006 , 27, 79-85		50
1331	Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2006 , 9, 167-81	4.3	225
1330	Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2006 , 9, 13-33	4.3	356
1329	Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2006 , 10, 89-109	4.3	256
1328	Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. 2006 , 96, 1005-15		173
1327	Development of evolutionary biomedicine as a novel direction of biological science. 2006 , 42, 505-514		
1326	Inflammation and metabolic disorders. 2006 , 444, 860-7		5854

1325	Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. 2006 , 11, 721-36	274
1324	Association of metabolic syndrome with Alzheimer disease: a population-based study. 2006 , 67, 843-7	227
1323	Alois Alzheimer revisited: differences in origin of the disease carrying his name. 2006 , 113, 1645-58	23
1322	Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice. 2006 , 49, 2153-61	23
1321	Risk of dementia in diabetes mellitus: a systematic review. 2006 , 5, 64-74	1424
1320	Sodium tungstate decreases the phosphorylation of tau through GSK3 inactivation. 2006 , 83, 264-73	25
1319	Inhibition of GSK3 dependent tau phosphorylation by metals. 2006 , 3, 123-7	21
1318	G-protein-coupled receptor rhodopsin regulates the phosphorylation of retinal insulin receptor. 2007 , 282, 9865-9873	39
1317	Alzheimer-like changes in rat models of spontaneous diabetes. 2007 , 56, 1817-24	219
1316	Intranasal insulin improves memory in humans: superiority of insulin aspart. 2007 , 32, 239-43	219
1315	Mechanistic insights into diabetes mellitus and oxidative stress. 2007 , 14, 1729-38	145
1314	Targeting insulin-like growth factor-1 to treat Alzheimer's disease. 2007 , 11, 1535-42	30
1313	Long-term abnormalities in brain glucose/energy metabolism after inhibition of the neuronal insulin receptor: implication of tau-protein. 2007 , 195-202	37
1312	BIBLIOGRAPHY. 2007 , 417-599	
1311	Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease. <i>Journal of Alzheimer's Disease</i> , 2007 , 12, 291-311	4-3 45
1310	Assessment of endocrine and nutritional status in age-related catabolic states of muscle and bone. 2007 , 10, 604-10	14
1309	Nitric oxide synthase 3-mediated neurodegeneration after intracerebral gene delivery. 2007 , 66, 272-83	14
1308	Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. 2007 , 28, 533-6	195

1307	Laser microdissection and microarray analysis of the hippocampus of Ras-GRF1 knockout mice reveals gene expression changes affecting signal transduction pathways related to memory and learning. 2007 , 146, 272-85	38
1306	Role of aspartyl-(asparaginyl) beta-hydroxylase in placental implantation: Relevance to early pregnancy loss. 2007 , 38, 50-9	22
1305	Redox chemistry and biological activities of chromium(III) complexes. 2007 , 225-256	13
1304	Neuropsychiatric Disorders An Integrative Approach. 2007 ,	4
1303	Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. 2007 , 32, 619-34	368
1302	Peripheral insulin and brain structure in early Alzheimer disease. 2007 , 69, 1094-104	88
1301	Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. 2007 , 257, 206-14	135
1300	Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. 2007 , 217-33	137
1299	Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function -- role of glucose metabolism and insulin signalling. 2007 , 113, 131-41	41
1298	Inflammation and schizophrenia. 2007 , 7, 789-96	88
1297	Interaction between serine phosphorylated IRS-1 and beta1-integrin affects the stability of neuronal processes. 2007 , 85, 2360-73	13
1296	Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. 2007 , 101, 757-70	269
1295	Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. 2007 , 14, 327-34	48
1294	Nerve growth factor prevents the apoptosis-associated increase in acetylcholinesterase activity after hydrogen peroxide treatment by activating Akt. 2007 , 39, 46-56	19
1293	Mitochondrial respiratory chain is involved in insulin-stimulated hydrogen peroxide production and plays an integral role in insulin receptor autophosphorylation in neurons. 2007 , 8, 84	50
1292	Common pathological processes in Alzheimer disease and type 2 diabetes: a review. 2007 , 56, 384-402	277
1291	The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. 2007 , 42, 10-21	153
1290	Dementia: The Significance of Cerebral Metabolic Disturbances in Alzheimer's Disease. Relation to Parkinson's Disease. 2007 , 189-232	

1289	Indices of metabolic dysfunction and oxidative stress. 2007 , 32, 717-22	21
1288	Molecular connexions between dementia and diabetes. 2007 , 31, 1046-63	119
1287	Vanadyl bisacetylacetonate induced G1/S cell cycle arrest via high-intensity ERK phosphorylation in HepG2 cells. 2008 , 13, 1001-9	45
1286	Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25-35)-induced amnesia. 2008 , 8, 1	23
1285	Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. 2008 , 86, 3265-74	211
1284	Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. 2008 , 9 Suppl 3, S5	399
1283	Amyloid beta oligomers induce impairment of neuronal insulin receptors. 2008 , 22, 246-60	431
1282	Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. 2008 , 32, 1630-44	46
1281	Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. 2008 , 106, 107-20	187
1280	Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. 2008 , 106, 1503-14	122
1279	Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. 2008 , 75, 1093-103	25
1278	The potential role of nutritional components in the management of Alzheimer's Disease. 2008 , 585, 197-207	29
1277	Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. 2008 , 585, 38-49	140
1276	Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair. 2008 , 585, 76-87	121
1275	Hypercholesterolemia-induced Abeta accumulation in rabbit brain is associated with alteration in IGF-1 signaling. 2008 , 32, 426-32	62
1274	Dirty electricity elevates blood sugar among electrically sensitive diabetics and may explain brittle diabetes. 2008 , 27, 135-46	24
1273	Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. 2008 , 60, 988-1009	324
1272	Regulation of brain insulin mRNA by glucose and glucagon-like peptide 1. 2008 , 376, 694-9	27

1271	Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease. 2008 , 18, 47-54		16
1270	Alzheimer's disease is type 3 diabetes-evidence reviewed. 2008 , 2, 1101-13		662
1269	Role of insulin metabolism disturbances in the development of Alzheimer disease: mini review. 2008 , 23, 192-9		20
1268	Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. 2008 , 99, 1590-5		69
1267	Mouse models of Alzheimer's dementia: current concepts and new trends. 2008 , 149, 5952-7		26
1266	Insulin Resistance Alzheimer's Disease: Pathophysiology and Treatment. 2008 , 3,		1
1265	Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. 2008 , 105, 1343-6		76
1264	Evidence that the etiology of the syndrome containing type 2 diabetes mellitus results from abnormal magnesium metabolism. 2008 , 86, 16-24		26
1263	Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. <i>Journal of Alzheimer's Disease</i> , 2008 , 15, 29-44	4-3	113
1262	Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. <i>Journal of Alzheimer's Disease</i> , 2008 , 14, 27-41	4-3	717
1261	An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2008 , 13, 241-53	4-3	67
1260	Growth factors as therapeutics for diabetic neuropathy. 2008 , 9, 47-59		60
1259	Value in development of a TAPIR-like mouse monoclonal antibody to Aβeta. <i>Journal of Alzheimer's Disease</i> , 2008 , 14, 175-7	4-3	2
1258	Mechanisms of ceramide-mediated neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2009 , 16, 705-14	4-3	53
1257	Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. <i>Journal of Alzheimer's Disease</i> , 2009 , 16, 585-99	4-3	58
1256	Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets. 2009 , 2, 250-286		8
1255	Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. <i>Journal of Alzheimer's Disease</i> , 2009 , 16, 715-29	4-3	103
1254	Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2009 , 17, 817-25	4-3	64

1253	Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. <i>Journal of Alzheimer's Disease</i> , 2009 , 18, 729-50	4-3	80
1252	Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. 2009 , 23, 3315-24		166
1251	Beneficial Effects of Fish Oil on Human Brain. 2009 ,		42
1250	The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. 2009 , 20, 1533-44		160
1249	Insulin signaling in sporadic Alzheimer's disease. 2009 , 2, pe36		29
1248	The relationship of diet and acne: A review. 2009 , 1, 262-7		20
1247	The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. 2009 , 6, 213-23		107
1246	Low density lipoprotein receptor-related protein 1 promotes anti-apoptotic signaling in neurons by activating Akt survival pathway. 2009 , 284, 34045-53		73
1245	Effects of exercise training on hippocampus concentrations of insulin and IGF-1 in diabetic rats. 2009 , 19, 981-7		25
1244	A dietary fat excess alters metabolic and neuroendocrine responses before the onset of metabolic diseases. 2009 , 29, 157-68		34
1243	Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. 2009 , 4, 54		56
1242	Distinct modulation of voltage-gated and ligand-gated Ca ²⁺ currents by PPAR-gamma agonists in cultured hippocampal neurons. 2009 , 109, 1800-11		60
1241	Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. 2009 , 111, 242-9		139
1240	Insulin is a two-edged knife on the brain. <i>Journal of Alzheimer's Disease</i> , 2009 , 18, 483-507	4-3	59
1239	Increased GH secretion in scrapie, a prion-associated neurodegenerative disease, is not due to suppressed IGF-1 negative feedback. 2009 , 36, 127-37		1
1238	Role of the JNK-interacting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes. 2009 , 80, 274-81		33
1237	Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. 2009 , 1792, 482-96		231
1236	(Pre)diabetes, brain aging, and cognition. 2009 , 1792, 432-43		238

1235	Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. 2009 , 205, 265-71		195
1234	Mechanisms involved in cholesterol-induced neuronal insulin resistance. 2009 , 57, 268-76		28
1233	Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLC/redox signaling pathway. 2009 , 162, 1212-9		99
1232	Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. 2009 , 89, 256-65		130
1231	Diagnosis and Management of Polycystic Ovary Syndrome. 2009 ,		0
1230	Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. 2009 , 29, 9078-89		411
1229	Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. 2009 , 175, 2089-98		173
1228	An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2009 , 16, 741-61	4-3	141
1227	Adiposity, type 2 diabetes, and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2009 , 16, 693-704	4-3	169
1226	Identification of Igf2, Igfbp2 and Enpp2 as estrogen-responsive genes in rat hippocampus. 2009 , 56, 113-20		41
1225	Diabetes Mellitus and Dementia.. 2010 , 99, 1678-1684		
1224	The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 1081-91	4-3	45
1223	Caffeine, diabetes, cognition, and dementia. <i>Journal of Alzheimer's Disease</i> , 2010 , 20 Suppl 1, S143-50	4-3	22
1222	Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 967-84	4-3	68
1221	A relationship between Alzheimer's disease and type 2 diabetes mellitus through the measurement of serum amyloid-beta autoantibodies. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 1371-6	4-3	18
1220	Understanding the molecular basis of Alzheimer's disease using a <i>Caenorhabditis elegans</i> model system. 2010 , 214, 263-83		42
1219	Rhodopsin-regulated insulin receptor signaling pathway in rod photoreceptor neurons. 2010 , 42, 39-47		21
1218	Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. 2010 , 630, 158-62		130

1217	Intranasal delivery to the central nervous system: mechanisms and experimental considerations. 2010 , 99, 1654-73		756
1216	Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration. 2010 , 10, 4		49
1215	Insulin receptor signaling in the development of neuronal structure and function. 2010 , 5, 7		147
1214	Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. 2010 , 5, 46		102
1213	NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. 2010 , 5, 49		109
1212	Insulin/PI3K signaling protects dentate neurons from oxygen-glucose deprivation in organotypic slice cultures. 2010 , 112, 377-88		38
1211	Insulin inhibits Aβ fibrillogenesis through a decrease of the GM1 ganglioside-rich microdomain in neuronal membranes. 2010 , 113, 628-36		9
1210	Intersection between metabolic dysfunction, high fat diet consumption, and brain aging. 2010 , 114, 344-61		61
1209	Ignoring the Evidence Will Not Stop the Alzheimer's Disease/Diabetes Pandemic. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 71-73	4-3	
1208	Glial vascular degeneration in CADASIL. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 1393-402	4-3	10
1207	Effects of long-term pioglitazone treatment on peripheral and central markers of aging. 2010 , 5, e10405		36
1206	Insulin levels are decreased in the cerebrospinal fluid of women with prodromal Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 405-13	4-3	57
1205	Neuronal insulin receptor substrate 2 (IRS2) expression is regulated by ZBP89 and SP1 binding to the IRS2 promoter. 2010 , 204, 199-208		9
1204	Response to earlier letter. 2010 , 39, 279-80; author reply 280		
1203	Insulin-like growth factor-1 (IGF-1)-induced processing of amyloid-beta precursor protein (APP) and APP-like protein 2 is mediated by different metalloproteinases. 2010 , 285, 10223-31		30
1202	Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AβPP-overexpressing mice. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 691-704	4-3	97
1201	GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 1205-19	4-3	233
1200	Hypothesis: intestinal barrier permeability may contribute to cognitive dysfunction and dementia. 2010 , 39, 278-9		3

1199	Diabetes and the Brain. 2010 ,	3
1198	Interactions between age, stress and insulin on cognition: implications for Alzheimer's disease. 2010 , 35, 1664-73	93
1197	Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease. 2010 , 106, 177-81	54
1196	Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention?. <i>Journal of Alzheimer's Disease</i> , 2010 , 20, 723-36	4-3 73
1195	Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. 2010 , 133, 1342-51	89
1194	The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain. 2010 , 24, 1965-77	31
1193	Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. 2010 , 5, 109-17	80
1192	Insulin resistance and increased lipolysis in bone marrow derived adipocytes stimulated with agonists of Toll-like receptors. 2010 , 42, 703-9	16
1191	Diabetes mellitus: channeling care through cellular discovery. 2010 , 7, 59-64	27
1190	Chronic exogenous corticosterone administration generates an insulin-resistant brain state in rats. 2010 , 13, 123-31	20
1189	Endocrine aspects of healthy brain aging. 2010 , 26, 57-74	6
1188	The Brain-insulin Connection, Metabolic Diseases and Related Pathologies. 2010 , 21-42	4
1187	Dementia, stroke and migraine--some common pathological mechanisms. 2010 , 299, 55-65	17
1186	Linking type 2 diabetes and Alzheimer's disease. 2010 , 107, 6557-8	68
1185	Neuroimmunomodulatory steroids in Alzheimer dementia. 2010 , 119, 97-104	14
1184	Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease. 2010 , 1800, 67-79	86
1183	Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. 2010 , 31, 224-43	532
1182	New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?. 2010 , 31, 1495-502	70

1181	Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. 2010 , 93, 546-53	272
1180	Sex differences in neuroactive steroid levels in the nervous system of diabetic and non-diabetic rats. 2010 , 57, 46-55	85
1179	Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. 2010 , 223, 422-31	123
1178	Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. 2010 , 77, 82-102	147
1177	PKC and Insulin Pathways in Memory Storage: Targets for Synaptogenesis, Anti-apoptosis, and the Treatment of AD. 2010 , 153-182	1
1176	Diabetes, Insulin and Alzheimer's Disease. 2010 ,	2
1175	The role of GLP-1 in neuronal activity and neurodegeneration. 2010 , 84, 331-54	47
1174	Drug penetration across the blood-brain barrier: an overview. 2010 , 1, 535-62	20
1173	Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. 2010 ,	74
1172	Vascular and metabolic dysfunction in Alzheimer's disease: a review. 2011 , 236, 772-82	76
1171	Insulin dysfunction and allostatic load in bipolar disorder. 2011 , 11, 1017-28	41
1170	Mitochondrial Uncoupling Proteins and Oxidative Stress: Implications for Diabetes and Neurodegeneration. 2011 , 1, 4-14	7
1169	Brain Imaging in Behavioral Medicine and Clinical Neuroscience. 2011 ,	5
1168	Nutrition and Skin. 2011 ,	0
1167	Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?. 2011 , 10, 264-73	161
1166	PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders. 2011 , 21, 292-303	26
1165	Nutrition and Alzheimer's disease: the detrimental role of a high carbohydrate diet. 2011 , 22, 134-40	67
1164	Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. 2011 , 60, 910-20	196

1163	The n-terminal 5-MER peptide analogue P165 of amyloid precursor protein exerts protective effects on SH-SY5Y cells and rat hippocampus neuronal synapses. 2011 , 173, 169-78	16
1162	The A β oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. 2011 , 96, 529-43	314
1161	Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. 2011 , 96, 432-42	137
1160	Reprint of: 'Brain insulin signaling: A key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes'. 2011 , 96, 517-28	15
1159	Insulin Resistance and Alzheimer's Disease. 2011 ,	1
1158	Type 2 Diabetes, the Metabolic Syndrome and Dyslipidemia in Children and Adolescents. 2011 , 159-173	
1157	Protein modification by dicarbonyl molecular species in neurodegenerative diseases. 2011 , 2011, 461216	11
1156	Protective Roles of the Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Hormones in Neurodegeneration. 2011 ,	
1155	Omega-3 polyunsaturated fatty acids in the brain: metabolism and neuroprotection. 2011 , 16, 2653-70	59
1154	A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. 2011 , 7, 10-8	54
1153	Proinsulin: from hormonal precursor to neuroprotective factor. 2011 , 4, 20	13
1152	The ϵ and δ alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. 2011 , 6, e16991	31
1151	Current understanding of HIV-associated neurocognitive disorders pathogenesis. 2011 , 24, 275-83	166
1150	ERK5: a novel IKK β kinase in rat hippocampal neurons. 2011 , 38, 639-48	5
1149	Long-term treatment with lithium alleviates memory deficits and reduces amyloid- β production in an aged Alzheimer's disease transgenic mouse model. <i>Journal of Alzheimer's Disease</i> , 2011 , 24, 739-49	4-3 76
1148	Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. 2011 , 71, 365-76	217
1147	Differential impact of diabetes and hypertension in the brain: adverse effects in white matter. 2011 , 42, 446-58	25
1146	Brain fuel metabolism, aging, and Alzheimer's disease. 2011 , 27, 3-20	374

1145	Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. 2011 , 46, 112-5	117
1144	Oxidative damage is present in the fatal brain edema of diabetic ketoacidosis. 2011 , 1369, 194-202	33
1143	Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes. 2011 , 15, 1153-62	25
1142	CSF A β levels and glucose metabolism in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2011 , 27, 845-51	4-3 17
1141	Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. 2011 , 118, 765-72	97
1140	JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. 2011 , 43, 376-90	117
1139	Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. 2011 , 225, 54-62	327
1138	Impact of STZ-induced hyperglycemia and insulin-induced hypoglycemia in plasma amino acids and cortical synaptosomal neurotransmitters. 2011 , 65, 457-66	24
1137	Inflammatory risk factors and pathologies associated with Alzheimer's disease. 2011 , 8, 132-41	45
1136	Insulin suppresses the expression of amyloid precursor protein, presenilins, and glycogen synthase kinase-3beta in peripheral blood mononuclear cells. 2011 , 96, 1783-8	14
1135	Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's Disease. 2011 , 9, 693-705	22
1134	Novel avenues of drug discovery and biomarkers for diabetes mellitus. 2011 , 51, 128-52	42
1133	Age-dependent accumulation of soluble amyloid beta (A β) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. 2011 , 286, 18414-25	141
1132	Insulin receptor substrate 2 is a negative regulator of memory formation. 2011 , 18, 375-83	45
1131	Mechanisms underlying insulin deficiency-induced acceleration of β amyloidosis in a mouse model of Alzheimer's disease. 2012 , 7, e32792	105
1130	Pancreatic function, type 2 diabetes, and metabolism in aging. 2012 , 2012, 320482	74
1129	Central obesity in the elderly is related to late-onset Alzheimer disease. 2012 , 26, 101-5	84
1128	Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment: a pilot clinical trial. 2012 , 69, 29-38	882

1127	Neurodegeneration: Recall sugars, forget Alzheimer's. 2012 , 8, 325-6		5
1126	Nutrition and dementia: are we asking the right questions?. <i>Journal of Alzheimer's Disease</i> , 2012 , 30, 27-33		16
1125	Pan-neuronal expression of APL-1, an APP-related protein, disrupts olfactory, gustatory, and touch plasticity in <i>Caenorhabditis elegans</i> . 2012 , 32, 10156-69		19
1124	PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. 2012 , 23, 3882-98		72
1123	Hyperphosphorylation of Tau induced by naturally secreted amyloid- β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3 β signaling pathway. 2012 , 287, 35222-35233		76
1122	Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. 2012 , 11, 482-9		25
1121	Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. 2012 , 441, 285-96		77
1120	Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. 2012 , 9, 35-66		301
1119	Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. <i>Journal of Alzheimer's Disease</i> , 2012 , 30 Suppl 2, S231-49	4-3	62
1118	Roles of Glucagon-Like Peptide and Glucose-Dependent Insulinotropic Polypeptide Hormones in Brain Function and Neurodegeneration. 2012 , 351-373		
1117	.		3
1116	.		2
1115	Down-regulation of amyloid- β through AMPK activation by inhibitors of GSK-3 β in SH-SY5Y and SH-SY5Y-APP695 cells. <i>Journal of Alzheimer's Disease</i> , 2012 , 29, 89-98	4-3	25
1114	Relative intake of macronutrients impacts risk of mild cognitive impairment or dementia. <i>Journal of Alzheimer's Disease</i> , 2012 , 32, 329-39	4-3	91
1113	Insulin to treat Alzheimer's disease: just follow your nose?. 2012 , 5, 17-20		16
1112	Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats. 2012 , 226, 62-72		72
1111	Increased A β production prompts the onset of glucose intolerance and insulin resistance. 2012 , 302, E1373-80		71
1110	Insulin and IGF-1 signalling: longevity, protein homeostasis and Alzheimer's disease. 2012 , 40, 721-7		98

1109	Obesity, insulin resistance, and Alzheimer's disease. 2012 , 20, 1549-57		51
1108	Changes in insulin-signaling transduction pathway underlie learning/memory deficits in an Alzheimer's disease rat model. 2012 , 119, 1407-16		16
1107	Positive argument for debate in J Neural Transmission: Alzheimer's disease: are we intervening too late? Yes, by years if not decades. 2012 , 119, 1529-32		6
1106	Co-location of HDAC2 and insulin signaling components in the adult mouse hippocampus. 2012 , 32, 1337-42		11
1105	Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?. 2012 , 8, 574-83		18
1104	Impaired neuronal insulin signaling precedes A β 2 accumulation in female APPsw/PS1E9 mice. <i>Journal of Alzheimer's Disease</i> , 2012 , 29, 783-91	4-3	52
1103	Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. 2012 , 33, 265-76		130
1102	Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents. 2012 , 33, 430.e5-18		58
1101	Heat shock response and insulin-associated neurodegeneration. 2012 , 33, 129-37		12
1100	Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. 2012 , 166, 1586-99		155
1099	O-GlcNAc cycling mutants modulate proteotoxicity in Caenorhabditis elegans models of human neurodegenerative diseases. 2012 , 109, 17669-74		74
1098	Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of rapamycin pathway. 2012 , 61, 3126-38		56
1097	Disease modifying drugs targeting β amyloid. 2012 , 27, 296-300		25
1096	Intranasal treatment of neurodegenerative diseases and stroke. 2012 , 4, 74-89		17
1095	Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging. 2012 , 1822, 333-9		50
1094	Focal adhesion kinase negatively regulates neuronal insulin resistance. 2012 , 1822, 1030-7		15
1093	Neuronal receptors as targets for the action of amyloid-beta protein (A β) in the brain. 2012 , 14, e2		40
1092	Insulin in central nervous system: more than just a peripheral hormone. 2012 , 2012, 384017		170

1091	Combined administration of cerebrolysin and donepezil induces plastic changes in prefrontal cortex in aged mice. 2012 , 66, 938-49	39
1090	Relationship between the neuroprotective effects of insulin-like growth factor-1 and 17 β estradiol in human neuroblasts. 2012 , 24, 1304-10	6
1089	Brain insulin resistance accelerates A β fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. 2012 , 121, 619-28	37
1088	Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. 2012 , 72, 49-66	150
1087	Insulin resistance in the brain: an old-age or new-age problem?. 2012 , 84, 737-45	54
1086	Identification of gene pathways implicated in Alzheimer's disease using longitudinal imaging phenotypes with sparse regression. 2012 , 63, 1681-94	60
1085	Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer's pathology. 2012 , 17, 705-18	46
1084	Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3 β inhibitors through virtual screening. 2012 , 22, 7232-6	14
1083	Beta-amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease. 2012 , 46, 605-13	26
1082	Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. 2012 , 8, 393-9	375
1081	Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. 2012 , 26, 871-82	122
1080	Infectious diseases: Transporter targeted in tuberculosis. 2012 , 8, 326-7	6
1079	Beating Around the Wrong Bush?. 2012 , 285-303	
1078	In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin. 2012 , 7, e46196	63
1077	Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease. 2012 , 7, e51432	37
1076	Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity. 2012 , 7, e52354	91
1075	Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer's disease cases. 2012 , 2012, 321280	13
1074	Intranasal treatment of neurodegenerative diseases and stroke. 2012 , S4, 74-89	23

1073	Metabolic and immune risk factors for dementia and their modification by flavonoids: New targets for the prevention of cognitive impairment?. 2012 , 1, 69-88	2
1072	Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. 2012 , 4, 1582-605	35
1071	Historical perspectives on the discovery and development of drugs to treat neurological disorders. 129-148	3
1070	Dementia [A Complete Literature Review on Various Mechanisms Involved in Pathogenesis and an Intracerebroventricular Streptozotocin Induced Alzheimer's Disease. 2012 ,	5
1069	Intrahippocampal administration of amyloid- β (1-42) oligomers acutely impairs spatial working memory, insulin signaling, and hippocampal metabolism. <i>Journal of Alzheimer's Disease</i> , 2012 , 30, 413-224-3	65
1068	Insulin: an emerging treatment for Alzheimer's disease dementia?. 2012 , 12, 520-7	45
1067	Amyloid- β oligomers induce differential gene expression in adult human brain slices. 2012 , 287, 7436-45	60
1066	Can Alzheimer disease be a form of type 3 diabetes?. 2012 , 15, 217-21	60
1065	Brain insulin signaling and Alzheimer's disease: current evidence and future directions. 2012 , 46, 4-10	129
1064	Thyroid hormone's role in regulating brain glucose metabolism and potentially modulating hippocampal cognitive processes. 2012 , 27, 101-11	14
1063	<i>Caenorhabditis elegans</i> as a model organism to study APP function. 2012 , 217, 397-411	22
1062	Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1 β and phosphorylates GSK3 β in P301L tau transgenic mice. 2012 , 219, 381-90	54
1061	Effect of chronic intracerebroventricular insulin administration in rats on the peripheral glucose metabolism and synaptic plasticity of CA1 hippocampal neurons. 2012 , 1435, 99-104	18
1060	Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. 2012 , 1441, 64-78	136
1059	Macular structure and function and the development of retinopathy in diabetes. 2012 , 95, 306-10	4
1058	Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. 2012 , 14, 214-21	91
1057	Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. 2012 , 14 Suppl 2, 41-9	20
1056	Alterations of central insulin-like growth factor-1 sensitivity in APP/PS1 transgenic mice and neuronal models. 2013 , 91, 717-25	20

1055	The effects of induced type-I diabetes on developmental regulation of insulin & insulin like growth factor-1 (IGF-1) receptors in the cerebellum of rat neonates. 2013 , 28, 397-410	16
1054	Hyperinsulinemia in rats causes impairment of spatial memory and learning with defects in hippocampal synaptic plasticity by involvement of postsynaptic mechanisms. 2013 , 226, 45-51	32
1053	Metabolic Syndrome. 2013 ,	24
1052	Impact of aerobic exercise on neurobehavioral outcomes. 2013 , 6, 139-153	28
1051	Neurogenic effects of β amyloid in the choroid plexus epithelial cells in Alzheimer's disease. 2013 , 70, 2787-97	14
1050	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. 2013 , 108, 21-43	368
1049	Molecular links between Alzheimer's disease and diabetes mellitus. 2013 , 250, 140-50	132
1048	Short-term estradiol administration in aging ovariectomized rats provides lasting benefits for memory and the hippocampus: a role for insulin-like growth factor-I. 2013 , 154, 842-52	42
1047	The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid- β plaque and glial pathology in a mouse model of Alzheimer's disease. 2013 , 15, 102-14	103
1046	Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. 2013 , 27, 505-14	329
1045	Hippocampal calcium dysregulation at the nexus of diabetes and brain aging. 2013 , 719, 34-43	22
1044	Non-cognitive symptoms and related conditions in the Alzheimer's disease: a literature review. 2013 , 34, 1275-82	22
1043	Disruption of neurogenesis by hypothalamic inflammation in obesity or aging. 2013 , 14, 351-6	23
1042	Glimepiride attenuates $A\beta$ production via suppressing BACE1 activity in cortical neurons. 2013 , 557 Pt B, 90-4	20
1041	Can lifestyle modification improve neurocognition? Rationale and design of the ENLIGHTEN clinical trial. 2013 , 34, 60-9	17
1040	Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?. 2013 , 18, 864-74	126
1039	Amyloid- β induces hepatic insulin resistance in vivo via JAK2. 2013 , 62, 1159-66	66
1038	What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research. 2013 , 120, 233-52	157

1037	Insulin receptor signaling mediates APP processing and β -amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease. 2013 , 35, 83-101	49
1036	Stress contributes to the development of central insulin resistance during aging: implications for Alzheimer's disease. 2013 , 1832, 2332-9	28
1035	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. 2013 , 38, 1729-37	51
1034	Sweet memories: 20 years of progress in research on cognitive functioning in diabetes. 2013 , 719, 153-160	13
1033	Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. 2013 , 1832, 527-41	90
1032	Complications of Diabetes Mellitus and their Pathophysiology. 2013 , 249-281	
1031	Food for thought: the role of appetitive peptides in age-related cognitive decline. 2013 , 12, 764-76	50
1030	Effect of high-fat diet on metabolic indices, cognition, and neuronal physiology in aging F344 rats. 2013 , 34, 1977-87	60
1029	Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders. 2013 , 47, 1045-65	68
1028	Cerebral energy metabolism and the brain's functional network architecture: an integrative review. 2013 , 33, 1347-54	57
1027	The olfactory system in Alzheimer's disease: Pathology, pathophysiology and pathway for therapy. 2013 , 4,	13
1026	O-GlcNAc cycling: a link between metabolism and chronic disease. 2013 , 33, 205-29	203
1025	Protection against the synaptic targeting and toxicity of Alzheimer's-associated A β oligomers by insulin mimetic chiro-inositols. 2013 , 27, 199-207	37
1024	A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). 2013 , 47, 711-25	169
1023	The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease. 2013 , 228, 294-300	69
1022	Alzheimer's disease and type 2 diabetes: two diseases, one common link?. 2013 , 14, 233-40	13
1021	Overlapped metabolic and therapeutic links between Alzheimer and diabetes. 2013 , 47, 399-424	60
1020	Maternal obesity affects gene expression and cellular development in fetal brains. 2013 , 16, 96-103	27

1019	Postindustrial Metabolism: Fat Knowledge. 2013 , 25, 495-522	57
1018	Nutrition and the risk of Alzheimer's disease. 2013 , 2013, 524820	96
1017	Cerebrolysin Ameliorates Cognitive Deficits in Type III Diabetic Rats. 2013 , 8, e64847	23
1016	Diabetes cognitive impairments and the effect of traditional chinese herbs. 2013 , 2013, 649396	12
1015	FK506 attenuates intracerebroventricular streptozotocin-induced neurotoxicity in rats. 2013 , 24, 580-9	16
1014	New animal models of Alzheimer's disease that display insulin desensitization in the brain. 2013 , 24, 607-15	26
1013	Insulin Resistance and Metabolic Failure Underlie Alzheimer Disease. 2013 , 1-30	2
1012	Insulin/IGF signaling-related gene expression in the brain of a sporadic Alzheimer's disease monkey model induced by intracerebroventricular injection of streptozotocin. <i>Journal of Alzheimer's Disease</i> , 2014 , 38, 251-67	4-3 35
1011	Type 3 diabetes linking a brain insulin-resistant state with dementia and Alzheimer's disease. 2013 , 30, 102-103	6
1010	In Vivo Evidence of the Convergence of Type 2 Diabetes and Alzheimer Disease. 2013 , 395-407	
1009	Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. 2013 , 3, e330	48
1008	Fitness, nutrition and the molecular basis of chronic disease. 2013 , 29, 1-23	3
1007	Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. 2013 , 10, 1699-709	51
1006	CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer's Disease. 2013 , 3, 128	25
1005	[Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment. Topics: 1. Pathophysiology, diagnosis and treatment; 2. Association between diabetes and dementia or depression]. 2013 , 102, 845-9	
1004	Adiponectin as a new paradigm for approaching Alzheimer's disease. 2013 , 46, 229-34	31
1003	Alzheimer's disease and insulin resistance: translating basic science into clinical applications. 2013 , 123, 531-9	229
1002	Selection of appropriate reference genes for RT-qPCR analysis in a streptozotocin-induced Alzheimer's disease model of cynomolgus monkeys (<i>Macaca fascicularis</i>). 2013 , 8, e56034	10

1001	Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer's disease. 2013 , 8, e69830	59
1000	Intranasal delivery of plasma and platelet growth factors using PRGF-Endoret system enhances neurogenesis in a mouse model of Alzheimer's disease. 2013 , 8, e73118	38
999	Amylin receptor: a common pathophysiological target in Alzheimer's disease and diabetes mellitus. 2013 , 5, 42	18
998	The Janus face of PAMAM dendrimers used to potentially cure nonenzymatic modifications of biomacromolecules in metabolic disorders-a critical review of the pros and cons. 2013 , 18, 13769-811	16
997	Persistence of HIV-Associated Neurocognitive Disorders in the Era of Antiretroviral Therapy. 2013 ,	
996	Neuronal Insulin Receptor Signaling: A Potential Target for the Treatment of Cognitive and Mood Disorders. 2013 ,	4
995	The relationship between serum insulin-like growth factor I levels and ischemic stroke risk. 2014 , 9, e94845	24
994	Molecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's disease. 2014 , 9, e105196	20
993	An update on drug treatment options of Alzheimer's disease. 2014 , 19, 1345-54	51
992	Chronic cerebral hypoperfusion causes decrease of O-GlcNAcylation, hyperphosphorylation of tau and behavioral deficits in mice. 2014 , 6, 10	59
991	A systematic review of type 2 diabetes mellitus and hypertension in imaging studies of cognitive aging: time to establish new norms. 2014 , 6, 148	30
990	Synchronizing an aging brain: can entraining circadian clocks by food slow Alzheimer's disease?. 2014 , 6, 234	17
989	Metabolic tinkering by the gut microbiome: Implications for brain development and function. 2014 , 5, 369-80	80
988	Does insulin therapy for type 1 diabetes mellitus protect against Alzheimer's disease?. 2014 , 34, 1317-23	17
987	Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits. <i>Journal of Alzheimer's Disease</i> , 2014 , 39, 145-62	4-3 62
986	Garlic extract attenuates brain mitochondrial dysfunction and cognitive deficit in obese-insulin resistant rats. 2014 , 39, 1373-9	27
985	SHIP2: a "new" insulin pathway target for aging research. 2014 , 17, 221-5	8
984	Association between risk factors for vascular dementia and adiponectin. 2014 , 2014, 261672	33

983	Use of <i>Caenorhabditis elegans</i> as a model to study Alzheimer's disease and other neurodegenerative diseases. 2014 , 5, 279	158
982	Importance of pH homeostasis in metabolic health and diseases: crucial role of membrane proton transport. 2014 , 2014, 598986	71
981	Functional MRI signal fluctuations: a preclinical biomarker for cognitive impairment in type 2 diabetes?. 2014 , 63, 396-8	2
980	A practical guide to genetic engineering of pancreatic β cells in vivo: getting a grip on RIP and MIP. 2014 , 6, e944439	12
979	Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. 2014 , 6, 1246-62	84
978	A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. 2014 , 28, 1185-9	36
977	Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis. 2014 , 23, 6528-41	55
976	DPP-4 inhibitor and PPAR α agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats. 2014 , 45, 547-52	26
975	Current challenges to overcome in the management of type 2 diabetes mellitus and associated neurological disorders. 2014 , 13, 1440-57	6
974	Your Brain on Insulin: From Heresy to Dogma. 2014 , 9, 88-90	1
973	Vascular risk factors aggravate the progression of Alzheimer's disease: a 3-year follow-up study of Chinese population. 2014 , 29, 521-5	10
972	Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. 2014 , 5, 161	278
971	Insulin resistance, neuroinflammation, and Alzheimer's disease. 2014 , 25, 509-25	39
970	Enhancement of β amyloid oligomer accumulation after intracerebroventricular injection of streptozotocin, which involves central insulin signaling in a transgenic mouse model. 2014 , 25, 1289-95	12
969	Perinatal exposure to Di-(2-ethylhexyl)-Phthalate leads to cognitive dysfunction and phospho-tau level increase in aged rats. 2014 , 29, 596-603	19
968	Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer's disease. 2014 , 1841, 793-8	49
967	Levels and actions of progesterone and its metabolites in the nervous system during physiological and pathological conditions. 2014 , 113, 56-69	93
966	Plasma rich in growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves cognitive functions in an Alzheimer's disease mouse model. 2014 , 35, 1582-95	27

965	Glaucoma--diabetes of the brain: a radical hypothesis about its nature and pathogenesis. 2014 , 82, 535-46	7
964	New insights concerning insulin synthesis and its secretion in rat hippocampus and cerebral cortex: amyloid- β -42-induced reduction of proinsulin level via glycogen synthase kinase-3 β 2014 , 26, 253-9	15
963	Specific induction of Akt3 in spinal cord motor neurons is neuroprotective in a mouse model of familial amyotrophic lateral sclerosis. 2014 , 49, 136-48	26
962	Gender differences and lateralization in the distribution pattern of insulin-like growth factor-1 receptor in developing rat hippocampus: an immunohistochemical study. 2014 , 34, 215-26	19
961	Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. 2014 , 14, 476	102
960	Amyloid beta-derived diffusible ligands (ADDLs) induce abnormal expression of insulin receptors in rat hippocampal neurons. 2014 , 52, 124-30	8
959	Is Alzheimer's disease a systemic disease?. 2014 , 1842, 1340-9	134
958	Spatial memory in sedentary and trained diabetic rats: molecular mechanisms. 2014 , 24, 703-11	23
957	Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): a paradigm worth exploring. 2014 , 88, 573-83	12
956	Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats. 2014 , 35, 741-51	49
955	Related genes and potential biomarkers for early diagnosis of Alzheimer's disease: a preliminary study based on DNA microarray. 2014 , 29, 90-5	3
954	Brain metabolic dysfunction at the core of Alzheimer's disease. 2014 , 88, 548-59	283
953	Injection of β amyloid into the hippocampus induces metabolic disturbances and involuntary weight loss which may be early indicators of Alzheimer's disease. 2014 , 26, 93-8	14
952	Zinc and the aging brain. 2014 , 9, 379	49
951	Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. 2014 , 36, 613-23	49
950	Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. 2014 , 35, 793-801	97
949	AGE aggravates cognitive deficit in rats via RAGE pathway. 2014 , 257, 1-10	31
948	Plant polyphenols in the treatment of age-associated diseases: revealing the pleiotropic effects of icariin by network analysis. 2014 , 58, 49-60	26

947	Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. 2014 , 128, 679-89	127
946	Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. 2014 , 4, 31-40	59
945	Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. 2014 , 221, T31-41	191
944	Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. 2014 , 463, 177-89	74
943	Adipokines and dementia. 2014 , 23, 185-189	
942	Insulin resistance in Alzheimer's disease. 2014 , 72 Pt A, 92-103	78
941	Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. 2014 , 63, 2262-72	354
940	Altered expression of diabetes-related genes in Alzheimer's disease brains: the Hisayama study. 2014 , 24, 2476-88	199
939	Lycopene attenuates insulin signaling deficits, oxidative stress, neuroinflammation, and cognitive impairment in fructose-drinking insulin resistant rats. 2014 , 86, 389-96	59
938	Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. 2014 , 42, 593-9	69
937	Ghrelin: a link between ageing, metabolism and neurodegenerative disorders. 2014 , 72 Pt A, 72-83	49
936	Cardiovascular risk factors and frontotemporal dementia: a case-control study. 2014 , 3, 13	22
935	Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. 2014 , 63, 2253-61	163
934	Relationships between diabetes and cognitive impairment. 2014 , 43, 245-67	54
933	Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. 2014 , 1842, 1693-706	230
932	Insulin reverses the high-fat diet-induced increase in brain A β and improves memory in an animal model of Alzheimer disease. 2014 , 63, 4291-301	150
931	Type 3 diabetes is sporadic Alzheimer's disease: mini-review. 2014 , 24, 1954-60	198
930	Deregulation of brain insulin signaling in Alzheimer's disease. 2014 , 30, 282-94	58

929	Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. 2014 , 14, 64		34
928	Metabolic syndrome and longitudinal changes in cognitive function: a systematic review and meta-analysis. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 151-61	4-3	70
927	Diabetes mellitus and disturbances in brain connectivity: a bidirectional relationship?. 2014 , 16, 658-68		23
926	Protection of streptozotocin induced insulin receptor dysfunction, neuroinflammation and amyloidogenesis in astrocytes by insulin. 2014 , 86, 337-52		33
925	NMDA receptors interact with the retrieval memory enhancing effect of pioglitazone in mice. 2014 , 126, 136-45		4
924	Intranasal therapeutic strategies for management of Alzheimer's disease. 2014 , 22, 279-94		57
923	How does brain insulin resistance develop in Alzheimer's disease?. 2014 , 10, S26-32		207
922	The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. 2014 , 10, S12-25		87
921	Acetyl-L-carnitine rescues scopolamine-induced memory deficits by restoring insulin-like growth factor II via decreasing p53 oxidation. 2014 , 76 Pt A, 80-7		27
920	Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. 2014 , 35, 1233-42		60
919	Insulin resistance and gray matter volume in neurodegenerative disease. 2014 , 270, 139-47		30
918	Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?. 2014 , 118, 1-18		143
917	Insulin action in brain regulates systemic metabolism and brain function. 2014 , 63, 2232-43		349
916	The pancreas-brain axis: insight into disrupted mechanisms associating type 2 diabetes and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2014 , 42, 347-56	4-3	27
915	Hippocampal apoptosis involved in learning deficits in the offspring exposed to maternal high sucrose diets. 2014 , 25, 985-90		29
914	Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces A β level and microglia activation in the brains of 3xTg-AD mice. 2014 , 261, 610-9		74
913	Early alterations in energy metabolism in the hippocampus of APP ^{swe} /PS1 ^{dE9} mouse model of Alzheimer's disease. 2014 , 1842, 1556-66		135
912	Ginsenosides attenuate methylglyoxal-induced impairment of insulin signaling and subsequent apoptosis in primary astrocytes. 2014 , 85, 215-23		22

911	Inositol hexakisphosphate kinase-1 regulates behavioral responses via GSK3 signaling pathways. 2014 , 19, 284-93		33
910	Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma. 2014 , 48, 287-94		56
909	Novel drug target identification for the treatment of dementia using multi-relational association mining. 2015 , 5, 11104		8
908	Rosiglitazone improves learning and memory ability in rats with type 2 diabetes through the insulin signaling pathway. 2015 , 350, 121-8		17
907	Impact of Insulin Degrading Enzyme and Nephilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 891-917	4-3	48
906	Central Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 715-28	4-3	78
905	Characterization of Cerebral Damage in a Monkey Model of Alzheimer's Disease Induced by Intracerebroventricular Injection of Streptozotocin. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 989-1005	4-3	27
904	Tobacco Smoke Exposure Impairs Brain Insulin/IGF Signaling: Potential Co-Factor Role in Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 373-86	4-3	21
903	Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Smoking in Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 133-48	4-3	24
902	Shared Genetic Etiology between Type 2 Diabetes and Alzheimer's Disease Identified by Bioinformatics Analysis. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 13-7	4-3	18
901	Neuropeptides II: function. 286-350		
900	Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 411-24	4-3	53
899	Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 48, 637-46	4-3	22
898	The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease. 2015 , 8, 82		30
897	The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 877-88	4-3	100
896	Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEε4 Carriers. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 525-33	4-3	48
895	DPP-4 Inhibitor Linagliptin Attenuates Aβ-Induced Cytotoxicity through Activation of AMPK in Neuronal Cells. 2015 , 21, 549-57		72
894	Depressive symptoms, cognitive impairment, and metabolic syndrome in community-dwelling elderly in Southern Taiwan. 2015 , 15, 109-115		5

893	Insulin resistance is an important risk factor for cognitive impairment in elderly patients with primary hypertension. 2015 , 56, 89-94	13
892	Gastrointestinal Surgery and Wernicke Encephalopathy. 2015 , 539-549	1
891	Mechanisms linking brain insulin resistance to Alzheimer's disease. 2015 , 9, 96-102	26
890	Metabolic Alterations Associated to Brain Dysfunction in Diabetes. 2015 , 6, 304-21	60
889	Effect of a Novel Polyherbal Formulation on Diabetes Induced Memory Deficits in Rats. 2015 , 05,	
888	The Gut Microflora and its Metabolites Regulate the Molecular Crosstalk between Diabetes and Neurodegeneration. 2015 , 06,	1
887	Diabetes and stem cell function. 2015 , 2015, 592915	21
886	Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. 2015 , 6, 282-99	75
885	Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer's disease. 2015 , 7, 94	67
884	Can insulin signaling pathways be targeted to transport A β out of the brain?. 2015 , 7, 114	20
883	Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration. 2015 , 9, 173	55
882	Aberrant insulin signaling in Alzheimer's disease: current knowledge. 2015 , 9, 204	178
881	Neuroinflammation is not a Prerequisite for Diabetes-induced Tau Phosphorylation. 2015 , 9, 432	7
880	Insulin Regulates the Activity of the High-Affinity Choline Transporter CHT. 2015 , 10, e0132934	7
879	Unaltered Prion Pathogenesis in a Mouse Model of High-Fat Diet-Induced Insulin Resistance. 2015 , 10, e0144983	12
878	Modulation of hippocampal neural plasticity by glucose-related signaling. 2015 , 2015, 657928	48
877	Diabetes Mellitus, Cognitive Impairment, and Traditional Chinese Medicine. 2015 , 2015, 810439	31
876	Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer's Disease. 2015 , 2015, 105828	263

875	Diabetes and Alzheimer disease, two overlapping pathologies with the same background: oxidative stress. 2015 , 2015, 985845	76
874	Structural Congruency of Ligand Binding to the Insulin and Insulin/Type 1 Insulin-like Growth Factor Hybrid Receptors. 2015 , 23, 1271-82	39
873	Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille's heel?. 2015 , 84, 69-77	24
872	High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiencies contribute to Alzheimer disease pathology in rodents. 2015 , 1852, 1687-99	105
871	The role of dietary coconut for the prevention and treatment of Alzheimer's disease: potential mechanisms of action. 2015 , 114, 1-14	122
870	Reduced cortical BACE1 content with one bout of exercise is accompanied by declines in AMPK, Akt, and MAPK signaling in obese, glucose-intolerant mice. 2015 , 119, 1097-104	35
869	Dementia and diabetes: Casual or causal relationship?. 2015 , 144, 176-180	
868	Chronic adjunction of 1-deoxynojirimycin protects from age-related behavioral and biochemical changes in the SAMP8 mice. 2015 , 37, 102	19
867	Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid- β Clearance. 2015 , 35, 11500-13	86
866	Insulin Resistance, Glucose Regulation, Obesity, and Mood. 2015 , 1-23	
865	Modulation of insulin signaling rescues BDNF transport defects independent of tau in amyloid- β oligomer-treated hippocampal neurons. 2015 , 36, 1378-82	23
864	Nutrition, Genes, and Neuroscience. 2015 , 1-13	1
863	Insulin resistance and cognitive dysfunction. 2015 , 444, 18-23	68
862	In vitro streptozotocin model for modeling Alzheimer-like changes: effect on amyloid precursor protein secretases and glycogen synthase kinase-3. 2015 , 122, 551-7	20
861	Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer's disease. 2015 , 122, 565-76	31
860	Alzheimer disease assessment scale-cognitive (ADAS-COG) en pacientes con diabetes mellitus tipo 2, con y sin neuropatía diabética periférica. 2015 , 7, 11-16	0
859	Amyloid β oligomer-induced ERK1/2-dependent serine 636/639 phosphorylation of insulin receptor substrate-1 impairs insulin signaling and glycogen storage in human astrocytes. 2015 , 561, 76-81	11
858	Western Diet and Cognitive Impairment. 2015 , 295-305	3

857	Nutritional Approaches to Mitigating Cognitive Decline and Maintaining Function in Alzheimer's Disease. 2015 , 837-845	
856	Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease. 2015 , 29, 4273-84	62
855	Vitamin D deficiency and Alzheimer disease: Common links. 2015 , 84, 84-98	39
854	The relationship between cognitive performance and insulin resistance in non-diabetic patients with mild cognitive impairment. 2015 , 30, 551-7	16
853	How to Stabilize Both the Proteins and the Membranes: Diverse Effects of sHsps in Neuroprotection. 2015 , 527-562	3
852	Proteome-wide characterization of signalling interactions in the hippocampal CA4/DG subfield of patients with Alzheimer's disease. 2015 , 5, 11138	34
851	Is Insulin Action in the Brain Relevant in Regulating Blood Glucose in Humans?. 2015 , 100, 2525-31	16
850	Exogenous Amyloid peptide interferes with GLUT4 localization in neurons. 2015 , 1615, 42-50	9
849	The role of type 2 diabetes in neurodegeneration. 2015 , 84, 22-38	163
848	Growth factor treatment to overcome Alzheimer's dysfunctional signaling. 2015 , 27, 1025-38	23
847	Minireview: Food for thought: regulation of synaptic function by metabolic hormones. 2015 , 29, 3-13	23
846	Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. 2015 , 10, 549-60	144
845	Short-lived diabetes in the young-adult ZDF rat does not exacerbate neuronal Ca(2+) biomarkers of aging. 2015 , 1621, 214-21	3
844	Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease. 2015 , 122, 577-92	63
843	Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain. 2015 , 35, 5851-9	79
842	Neuronal stress signaling and eIF2 γ phosphorylation as molecular links between Alzheimer's disease and diabetes. 2015 , 129, 37-57	46
841	Differential Contributions of Alcohol and the Nicotine-Derived Nitrosamine Ketone (NNK) to Insulin and Insulin-Like Growth Factor Resistance in the Adolescent Rat Brain. 2015 , 50, 670-9	17
840	Linking insulin with Alzheimer's disease: emergence as type III diabetes. 2015 , 36, 1763-9	37

839	Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide 2015 , 22, 133-45	31
838	Association between metabolic syndrome and mild cognitive impairment and its age difference in a Chinese community elderly population. 2015 , 82, 844-53	32
837	Parameters of glucose metabolism and the aging brain: a magnetization transfer imaging study of brain macro- and micro-structure in older adults without diabetes. 2015 , 37, 9802	7
836	Hippocampal insulin resistance and cognitive dysfunction. 2015 , 16, 660-71	313
835	Glucose deprivation increases tau phosphorylation via P38 mitogen-activated protein kinase. 2015 , 14, 1067-74	23
834	Insulin and IGF1 signalling pathways in human astrocytes in vitro and in vivo; characterisation, subcellular localisation and modulation of the receptors. 2015 , 8, 51	53
833	Alzheimer: Prävention mit dem Kochtopf!. 2015 , 2, 15-18	
832	Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice. 2015 , 412, 95-103	19
831	Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study. 2015 , 5, 51-63	24
830	Synopsis on the linkage of Alzheimer's and Parkinson's disease with chronic diseases. 2015 , 21, 1-7	23
829	[Dementia and diabetes: casual or causal relationship?]. 2015 , 144, 176-80	3
828	Potential benefits of mindfulness-based interventions in mild cognitive impairment and Alzheimer's disease: an interdisciplinary perspective. 2015 , 276, 199-212	51
827	Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms. 2015 , 22, 4-13	45
826	Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models. 2015 , 31, 1-13	47
825	Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression. 2015 , 36, 1451-61	75
824	Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice. 2015 , 122, 593-606	41
823	Diabetes mellitus and cognitive impairments. 2016 , 7, 412-22	121
822	Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. 2016 , 6,	24

821	Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia. 2016 , 22, 812-8		45
820	Biological and biophysics aspects of metformin-induced effects: cortex mitochondrial dysfunction and promotion of toxic amyloid pre-fibrillar aggregates. 2016 , 8, 1718-34		37
819	Alzheimer's Disease: From Animal Models to the Human Syndrome. 2016 ,		0
818	Short-Term High-Fat Diet (HFD) Induced Anxiety-Like Behaviors and Cognitive Impairment Are Improved with Treatment by Glyburide. 2016 , 10, 156		49
817	Diabetes Mellitus Induces Alzheimer's Disease Pathology: Histopathological Evidence from Animal Models. 2016 , 17, 503		61
816	The Rationale for Insulin Therapy in Alzheimer's Disease. 2016 , 21,		11
815	Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease. 2016 , 11, e0155733		28
814	The Influences of Dietary Sugar and Related Metabolic Disorders on Cognitive Aging and Dementia. 2016 , 331-344		3
813	The amyloid cascade hypothesis: are we poised for success or failure?. 2016 , 139 Suppl 2, 237-252		235
812	Quantitative shotgun proteomics reveals extensive changes to the proteome of the orbitofrontal cortex in rats that are hyperactive following withdrawal from a high sugar diet. 2016 , 16, 657-73		8
811	JNK: A Putative Link Between Insulin Signaling and VGLUT1 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 963-7	4-3	2
810	T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 51, 123-38	4-3	29
809	Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 849-864	4-3	45
808	SH2B1 is Involved in the Accumulation of Amyloid- β 2 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 835-847	4-3	7
807	Glucose Transporters in Brain: In Health and in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 1307-1320	4-3	100
806	Intranasal Insulin Prevents Anesthesia-Induced Spatial Learning and Memory Deficit in Mice. 2016 , 6, 21186		40
805	Lipid microdomain modification sustains neuronal viability in models of Alzheimer's disease. 2016 , 4, 103		19
804	Brain-Specific Basal and Novelty-Induced Alternations in PI3K-Akt and MAPK/ERK Signaling in a Middle-Aged APP/PS1 Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 51, 1157-73	4-3	15

803	Alzheimer's disease: Is this a brain specific diabetic condition?. 2016 , 164, 259-67	32
802	Diabetes mellitus and Alzheimer's disease: An unforgettable relation. 2016 , 63, 191-193	1
801	Cerebral cortex: a target and source of insulin?. 2016 , 59, 1609-15	32
800	Altered Insulin Resistance and the Effects of Insulin on the Cholesterol Synthesis Pathway and Altered Secretion in Neural Cells. 2016 , 32, 227-38	20
799	Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects. 2016 , 12, 1287-98	71
798	A multipronged, nutritional-based strategy for managing Alzheimer's disease. 2016 , 91, 98-102	2
797	SIRT2 regulates insulin sensitivity in insulin resistant neuronal cells. 2016 , 474, 747-752	13
796	Relative expression of the p75 neurotrophin receptor, tyrosine receptor kinase A, and insulin receptor in SH-SY5Y neuroblastoma cells and hippocampi from Alzheimer's disease patients. 2016 , 101, 22-29	7
795	Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease. 2016 , 32, 591-596	32
794	Autophagy resolves early retinal inflammation in Igf1-deficient mice. 2016 , 9, 965-74	12
793	Oral inflammation and infection, and chronic medical diseases: implications for the elderly. 2016 , 72, 153-75	137
792	Neuronal DNA damage response-associated dysregulation of signalling pathways and cholesterol metabolism at the earliest stages of Alzheimer-type pathology. 2016 , 42, 167-79	21
791	Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease. 2016 , 241, 1676-83	27
790	Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans. 2016 , 96, 1169-209	251
789	Novel Roles for the Insulin-Regulated Glucose Transporter-4 in Hippocampally Dependent Memory. 2016 , 36, 11851-11864	68
788	Lack of insulin results in reduced seladin-1 expression in primary cultured neurons and in cerebral cortex of STZ-induced diabetic rats. 2016 , 633, 174-181	8
787	Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?. 2016 , 213, 1375-85	113
786	Aberrant protein phosphorylation in Alzheimer disease brain disturbs pro-survival and cell death pathways. 2016 , 1862, 1871-82	48

785	Insulin signalling in Alzheimer's disease and diabetes: from epidemiology to molecular links. 2016 , 280, 430-442	49
784	Hydralazine inhibits amyloid beta (A β) aggregation and glycation and ameliorates A β 2 induced neurotoxicity. 2016 , 6, 108768-108776	4
783	The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease. 2016 , 36, 1305-1315	13
782	High glucose upregulates BACE1-mediated A β production through ROS-dependent HIF-1 α and LXR β /ABCA1-regulated lipid raft reorganization in SK-N-MC cells. 2016 , 6, 36746	46
781	Chitotriosidase: A New Inflammatory Marker in Diabetic Complications. 2016 , 83, 211-9	21
780	Type 2 Diabetes, Obesity, and Risk for Dementia: Recent Insights into Brain Insulin Resistance and Hypometabolism. 2016 , 3, 293-300	3
779	Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer's and Parkinson's disease. 2016 , 5, 93-98	22
778	Patients with rosacea have increased risk of dementia. 2016 , 79, 921-8	29
777	Prospects and Challenges for Alzheimer Therapeutics. 2016 , 605-637	0
776	Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?. 2016 , 48, 614-624	59
775	Wnt3a upregulates brain-derived insulin by increasing NeuroD1 via Wnt/ β catenin signaling in the hypothalamus. 2016 , 9, 24	18
774	Role of metabolism in neurodegenerative disorders. 2016 , 65, 1376-90	111
773	Type 2 diabetes mellitus as a risk factor for dementia in a Mexican population. 2016 , 30, 1234-9	8
772	The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease. 2016 , 53, 905-931	61
771	Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level. 2016 , 70, 68-75	14
770	Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease. 2016 , 105, 186-97	33
769	Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm. 2016 , 91, 127-42	74
768	The Ames dwarf mutation attenuates Alzheimer's disease phenotype of APP/PS1 mice. 2016 , 40, 22-40	16

767	Lipoic acid improves neuronal insulin signalling and rescues cognitive function regulating VGlut1 expression in high-fat-fed rats: Implications for Alzheimer's disease. 2016 , 1862, 511-517	15
766	Inhibitory Effect of Memantine on Streptozotocin-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Neurotrophic Factor Decline in Astrocytes. 2016 , 53, 6730-6744	18
765	Sex differences between APPswePS1dE9 mice in A-beta accumulation and pancreatic islet function during the development of Alzheimer's disease. 2016 , 50, 275-85	15
764	Decreased IDE and IGF2 expression but increased A β 0 in the cerebral cortex of mouse pups by early life lead exposure. 2016 , 121, 84-90	9
763	Therapeutically relevant structural and functional mechanisms triggered by physical and cognitive exercise. 2016 , 21, 1633-1642	99
762	Efectos del ejercicio ffsico y pautas bbasicas para su prescripci3n en la enfermedad de Alzheimer. 2016 , 9, 32-40	1
761	The rise and fall of insulin signaling in Alzheimer's disease. 2016 , 31, 497-515	33
760	Calcitriol prevents peripheral RSC96 Schwann neural cells from high glucose & methylglyoxal-induced injury through restoration of CBS/H2S expression. 2016 , 92, 49-57	19
759	Brain metabolism as a modulator of autophagy in neurodegeneration. 2016 , 1649, 158-165	14
758	Insulin-Like Growth Factor-1 Receptor Is Differentially Distributed in Developing Cerebellar Cortex of Rats Born to Diabetic Mothers. 2016 , 58, 221-32	6
757	Apolipoprotein E and Amyloid- β -Independent Mechanisms in Alzheimer's Disease. 2016 , 171-196	1
756	Quantitative Proteomic Analysis of the Orbital Frontal Cortex in Rats Following Extended Exposure to Caffeine Reveals Extensive Changes to Protein Expression: Implications for Neurological Disease. 2016 , 15, 1455-71	4
755	Diabetes and Alzheimer's disease crosstalk. 2016 , 64, 272-87	104
754	Diabetes mellitus and Alzheimer's disease: An unforgettable relation. 2016 , 63, 191-3	3
753	Ionizing radiation-engineered nanogels as insulin nanocarriers for the development of a new strategy for the treatment of Alzheimer's disease. 2016 , 80, 179-194	56
752	Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin. 2016 , 39, 19-24	21
751	Brain Insulin Administration Triggers Distinct Cognitive and Neurotrophic Responses in Young and Aged Rats. 2016 , 53, 5807-5817	27
750	Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology. 2016 , 53, 4548-62	64

749	Intracerebroventricular Streptozotocin Injections as a Model of Alzheimer's Disease: in Search of a Relevant Mechanism. 2016 , 53, 1741-1752		159
748	Type 2 Diabetes. 2016 ,		2
747	Anti-diabetic and neuroprotective effects of pancreatic islet transplantation into the central nervous system. 2016 , 32, 11-20		9
746	Cognitive function and insulin resistance in elderly patients with type 2 diabetes. 2017 , 39, 259-263		12
745	Curcumin regulates insulin pathways and glucose metabolism in the brains of APPswe/PS1dE9 mice. 2017 , 30, 25-43		26
744	Neurocognitive impairment in patients with comorbid diabetes mellitus and depression. 2017 , 1-2, 2-10		2
743	The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid- β , Amylin, and Tau Proteins. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 421-432	4-3	108
742	Fluoride Alteration of [H]Glucose Uptake in Wistar Rat Brain and Peripheral Tissues. 2017 , 31, 436-443		8
741	Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer's disease-like tau pathology. 2017 , 7, 463-59		40
740	References. 2017 , 301-354		
739	Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease. 2017 , 82, 23-34		9
738	Insulin deficiency results in reversible protein kinase A activation and tau phosphorylation. 2017 , 103, 163-173		18
737	Pioglitazone improves the ability of learning and memory via activating ERK1/2 signaling pathway in the hippocampus of T2DM rats. 2017 , 651, 165-170		5
736	The effects of aging in the hippocampus and cognitive decline. 2017 , 79, 66-86		186
735	Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer's disease?. 2017 , 124, 695-708		22
734	Health equality, social justice and the poverty of autonomy. 2017 , 12, 411-433		6
733	Effect of insulin on spatial memory in aluminum chloride-induced dementia in rats. 2017 , 28, 540-544		16
732	Protein Phosphorylation is a Key Mechanism in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 953-978	4-3	38

731	The Mechanisms of Action of Curcumin in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 1003-1016	4-3	116
730	The emerging link between O-GlcNAcylation and neurological disorders. 2017 , 74, 3667-3686		26
729	Multiple functions of insulin-degrading enzyme: a metabolic crosslight?. 2017 , 52, 554-582		49
728	The underexplored question of Amyloid monomers. 2017 , 817, 71-75		17
727	Retinal neurovascular changes appear earlier in type 2 diabetic patients. 2017 , 27, 346-351		24
726	Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study. 2017 , 31, 107-113		157
725	The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons. 2017 , 140, 2012-2027		32
724	Lipidomic Profiles in Diabetes and Dementia. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 433-444	4-3	21
723	Computational and structural evidence for neurotransmitter-mediated modulation of the oligomeric states of human insulin in storage granules. 2017 , 292, 8342-8355		12
722	Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer's rat model. 2017 , 7, 45971		66
721	Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice. 2017 , 42, 2326-2335 ⁴¹		
720	Central Regulation of Glucose Homeostasis. 2017 , 7, 741-764		37
719	Associations of polymorphisms in the candidate genes for Alzheimer's disease BIN1, CLU, CR1 and PICALM with gestational diabetes and impaired glucose tolerance. 2017 , 44, 227-231		6
718	Hypoxia-inducible factors as neuroprotective agent in Alzheimer's disease. 2017 , 44, 327-334		64
717	Glucose tolerance and insulin sensitivity are impaired in APP/PS1 transgenic mice prior to amyloid plaque pathogenesis and cognitive decline. 2017 , 88, 9-18		39
716	Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease. 2017 , 77, 47-65		144
715	Long-term high-fat diet induces hippocampal microvascular insulin resistance and cognitive dysfunction. 2017 , 312, E89-E97		40
714	The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease. 2017 , 123, 192-198		86

713	HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation. 2017 , 187, 91-109	20
712	Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. 2017 , 96, 115-129.e5	138
711	N-Methyl-D aspartate receptor-mediated effect on glucose transporter-3 levels of high glucose exposed-SH-SY5Y dopaminergic neurons. 2017 , 109, 465-471	7
710	Suppression of adiponectin receptor 1 promotes memory dysfunction and Alzheimer's disease-like pathologies. 2017 , 7, 12435	31
709	Low serum insulin-like growth factor-I (IGF-I) level is associated with increased risk of vascular dementia. 2017 , 86, 169-175	13
708	Progressive white matter atrophy with altered lipid profiles is partially reversed by short-term abstinence in an experimental model of alcohol-related neurodegeneration. 2017 , 65, 51-62	13
707	Central and peripheral circadian clocks and their role in Alzheimer's disease. 2017 , 10, 1187-1199	31
706	Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons. 2017 , 140, 3269-3285	48
705	Impact of morphine on the expression of insulin receptor and protein levels of insulin/IGFs in rat neural stem cells. 2017 , 660, 147-154	2
704	Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders. 2017 , 18, 113-142	31
703	Transcriptional regulation of APP by apoE: To boldly go where no isoform has gone before: ApoE, APP transcription and AD: Hypothesised mechanisms and existing knowledge gaps. 2017 , 39, 1700062	7
702	Differential effects of blood insulin and HbA1c on cerebral amyloid burden and neurodegeneration in nondiabetic cognitively normal older adults. 2017 , 59, 15-21	13
701	Type 3 diabetes: a brain insulin-resistant state linked to Alzheimer's disease. 2017 , 34, 187-188	5
700	DPP4 Inhibitors Can Be a Drug of Choice for Type 3 Diabetes: A Mini Review. 2017 , 32, 444-451	12
699	Computational prediction of the phenotypic effects of genetic variants: basic concepts and some application examples in Drosophila nervous system genes. 2017 , 31, 307-319	1
698	Lychee seed extract protects against neuronal injury and improves cognitive function in rats with type II diabetes mellitus with cognitive impairment. 2018 , 41, 251-263	16
697	C-myb Plays an Essential Role in the Protective Function of IGF-1 on Cytotoxicity Induced by Aβ via the PI3K/Akt Pathway. 2017 , 63, 412-418	6
696	Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. 2017 , 74, 3769-3787	244

695	Animal Models of Alzheimer's Disease. 2017 , 1031-1085		9
694	Brain function and structure and risk for incident diabetes: The Atherosclerosis Risk in Communities Study. 2017 , 13, 1345-1354		7
693	Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration. 2017 , 71, e21990		96
692	Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease. 2017 , 58, 1-13		47
691	Mild cognitive impairment in type 2 diabetes mellitus and related risk factors: a review. 2017 , 28, 715-723		40
690	Multiple Mechanisms Linking Type 2 Diabetes and Alzheimer's Disease: Testosterone as a Modifier. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 445-466	4-3	22
689	Dexamethasone Alters the Appetite Regulation via Induction of Hypothalamic Insulin Resistance in Rat Brain. 2017 , 54, 7483-7496		16
688	Sorting receptor SORLA: cellular mechanisms and implications for disease. 2017 , 74, 1475-1483		25
687	The pertussis hypothesis: Bordetella pertussis colonization in the pathogenesis of Alzheimer's disease. 2017 , 222, 228-240		9
686	Blockade of Glutamine Synthetase Enhances Inflammatory Response in Microglial Cells. 2017 , 26, 351-363		42
685	Autophagy-lysosome dysfunction is involved in A β deposition in STZ-induced diabetic rats. 2017 , 320, 484-493		28
684	Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. 2017 , 1863, 1078-1089		257
683	TLR4 is a link between diabetes and Alzheimer's disease. 2017 , 316, 234-244		67
682	mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. 2017 , 13, 152-167		48
681	Brain Function Is Linked to LDL Cholesterol in Older Adults with Cardiovascular Risk. 2017 , 65, e51-e55		8
680	Insulin-like growth factor-1 protects SH-SY5Y cells against β amyloid-induced apoptosis via the PI3K/Akt-Nrf2 pathway. 2017 , 87, 23-32		18
679	The Triangle of Death in Alzheimer's Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics. 2017 , 26, 364-387		82
678	Modification of membrane lipids protects neurons against insulin resistance in models of Alzheimer's disease. 2017 , 23,		2

677	Veränderung von Membranlipiden schützt vor neuronaler Insulinresistenz in Alzheimer-Modellen. 2017 , 23, 212-222		
676	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 309-320	4-3	19
675	A Brief Review of Caprylidene (Axona) and Coconut Oil as Alternative Fuels in the Fight Against Alzheimer's Disease. 2017 , 32, 748-751		1
674	Mevastatin promotes neuronal survival against A β -induced neurotoxicity through AMPK activation. 2017 , 32, 1999-2007		8
673	Diabetes Mellitus and Alzheimer's Disease: The Protection of Epigallocatechin-3-gallate in Streptozotocin Injection-Induced Models. 2017 , 8, 834		15
672	Potential Neuroprotective Effects of Adiponectin in Alzheimer's Disease. 2017 , 18,		33
671	From Sea to Shining Sea and the Great Plains to Patagonia: A Review on Current Knowledge of Diabetes Mellitus in Hispanics/Latinos in the US and Latin America. 2017 , 8, 298		21
670	Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease. 2017 , 9, 118		72
669	Divergent Metabolic Regulation of Autophagy and mTORC1-Early Events in Alzheimer's Disease?. 2017 , 9, 173		16
668	Insulin-Like Growth Factor 1: At the Crossroads of Brain Development and Aging. 2017 , 11, 14		98
667	Conditional Deletion of PDK1 in the Forebrain Causes Neuron Loss and Increased Apoptosis during Cortical Development. 2017 , 11, 330		13
666	Aerobic-Strength Exercise Improves Metabolism and Clinical State in Parkinson's Disease Patients. 2017 , 8, 698		14
665	Cerebral Pathology and Cognition in Diabetes: The Merits of Multiparametric Neuroimaging. 2017 , 11, 188		14
664	The role of melatonin in the onset and progression of type 3 diabetes. 2017 , 10, 35		11
663	The Novel Implication of Androgen in Diabetes-induced Alzheimer's Disease. 2017 , 6, 66		1
662	Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease. 2017 , 58, 479-488		61
661	Chronic diabetic states worsen Alzheimer neuropathology and cognitive deficits accompanying disruption of calcium signaling in leptin-deficient APP/PS1 mice. 2017 , 8, 43617-43634		18
660	A REVIEW ON ALZHEIMER'S DISEASE: PATHOLOGY, MOLECULAR CONDITIONS, MANAGEMENT AND CAUSES. 2017 , 10, 27		3

659	Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain. 2018 , 5, 262-272		30
658	Brain insulin signalling, glucose metabolism and females' reproductive aging: A dangerous triad in Alzheimer's disease. 2018 , 136, 223-242		26
657	Warning SINEs: Alu elements, evolution of the human brain, and the spectrum of neurological disease. 2018 , 26, 93-111		37
656	Brain alpha-amylase: a novel energy regulator important in Alzheimer disease?. 2018 , 28, 920-932		18
655	Mutual Relationship between Tau and Central Insulin Signalling: Consequences for AD and Tauopathies?. 2018 , 107, 181-195		20
654	Etiology of type 2 diabetes and Alzheimer's disease: Exploring the mitochondria. 2018 , 43, 16-24		29
653	Age-Dependent Changes to Sphingolipid Balance in the Human Hippocampus are Gender-Specific and May Sensitize to Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 503-514	4-3	23
652	Insulin receptor in the brain: Mechanisms of activation and the role in the CNS pathology and treatment. 2018 , 24, 763-774		68
651	Computational insights into ßite amyloid precursor protein enzyme 1 (BACE1) inhibition by tanshinones and salvianolic acids from <i>Salvia miltiorrhiza</i> via molecular docking simulations. 2018 , 74, 273-285		11
650	Evidence for Compromised Insulin Signaling and Neuronal Vulnerability in Experimental Model of Sporadic Alzheimer's Disease. 2018 , 55, 8916-8935		17
649	Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer's disease. 2018 , 68, 1		24
648	Effects of Metformin on Spatial and Verbal Memory in Children with ASD and Overweight Associated with Atypical Antipsychotic Use. 2018 , 28, 266-273		4
647	Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1417-1441	4-3	60
646	Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. 2018 , 14, 168-181		505
645	Population-Based Cohort Study on Dementia Risk in Patients with Type 1 Diabetes Mellitus. 2018 , 50, 57-62		10
644	Insulin Resistance is Associated with Cognitive Decline Among Older Koreans with Normal Baseline Cognitive Function: A Prospective Community-Based Cohort Study. 2018 , 8, 650		18
643	Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. 2018 , 136, 251-259		86
642	Synaptic plasticity modulation by circulating peptides and metaplasticity: Involvement in Alzheimer's disease. 2018 , 130, 385-401		20

641	Evidence for altered insulin receptor signaling in Alzheimer's disease. 2018 , 136, 202-215		28
640	Leptin and ghrelin: Sewing metabolism onto neurodegeneration. 2018 , 136, 307-316		21
639	Mechanism of intranasal drug delivery directly to the brain. 2018 , 195, 44-52		232
638	A preclinical perspective on the enhanced vulnerability to Alzheimer's disease after early-life stress. 2018 , 8, 172-185		22
637	Targeting Insulin for Alzheimer's Disease: Mechanisms, Status and Potential Directions. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S427-S453	4-3	14
636	Considering sex differences in the cognitive controls of feeding. 2018 , 187, 97-107		11
635	The 20-Year Voyage Aboard the Journal of Alzheimer's Disease: Docking at 'Type 3 Diabetes', Environmental/Exposure Factors, Pathogenic Mechanisms, and Potential Treatments. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1381-1390	4-3	29
634	Multifactorial Hypothesis and Multi-Targets for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S107-S117	4-3	67
633	Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S405-S426	4-3	36
632	Neuroactive steroids and diabetic complications in the nervous system. 2018 , 48, 58-69		21
631	Intranasal Insulin Ameliorates Cerebral Hypometabolism, Neuronal Loss, and Astroglialosis in Streptozotocin-Induced Alzheimer's Rat Model. 2018 , 33, 716-724		22
630	Reduced brain insulin signaling: A seminal process in Alzheimer's disease pathogenesis. 2018 , 136, 192-195		22
629	Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders. 2018 , 43, 295-310		65
628	Hospital Admissions in People With Alzheimer's Disease or Senile Dementia According to Type 2 Diabetes Status: An Observational 10-Year Study. 2018 , 33, 12-19		3
627	Intranasal insulin treatment restores cognitive deficits and insulin signaling impairment induced by repeated methamphetamine exposure. 2018 , 119, 2345-2355		22
626	Shared pathological pathways of Alzheimer's disease with specific comorbidities: current perspectives and interventions. 2018 , 144, 360-389		8
625	Intranasal insulin in Alzheimer's disease: Food for thought. 2018 , 136, 196-201		53
624	Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease. 2018 , 67, 79-86		10

623	A β inhibits SREBP-2 activation through Akt inhibition. 2018 , 59, 1-13	6
622	Insulin-mediated synaptic plasticity in the CNS: Anatomical, functional and temporal contexts. 2018 , 136, 182-191	55
621	Hidden heterogeneity in Alzheimer's disease: Insights from genetic association studies and other analyses. 2018 , 107, 148-160	27
620	Diabetes mellitus and Alzheimer's disease: GSK-3 β as a potential link. 2018 , 339, 57-65	110
619	Impaired peripheral glucose homeostasis and Alzheimer's disease. 2018 , 136, 172-181	42
618	Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets. 2018 , 136, 160-171	70
617	Periodontal disease exacerbates Alzheimer's disease. 2018 , 60, 147-152	
616	Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies. 2018 , 15, 283-300	101
615	For Your Patients-Dementia. 2018 , 18, 20-21	
614	6 .Diagnostische Methoden. 2018 , 187-352	
613	The Role of Long Noncoding RNAs in Diabetic Alzheimer's Disease. 2018 , 7,	7
612	The Effect of Adherence to Screening Guidelines on the Risk of Alzheimer's Disease in Elderly Individuals Newly Diagnosed With Type 2 Diabetes Mellitus. 2018 , 4, 2333721418811201	5
611	Insulin Peptides as Mediators of the Impact of Life Style in Alzheimer's disease. 2018 , 4, 3-15	9
610	Intranasal Insulin Prevents Anesthesia-induced Cognitive Impairments in Aged Mice. 2019 , 16, 8-18	14
609	Serum Ethanolamine Plasmalogen and Urine Myo-Inositol as Cognitive Decline Markers. 2018 , 87, 69-111	3
608	Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 11-23	4-3 9
607	Redox Balance, Antioxidant Defense, and Oxidative Damage in the Hypothalamus and Cerebral Cortex of Rats with High Fat Diet-Induced Insulin Resistance. 2018 , 2018, 6940515	50
606	Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging. 2018 , 9, 880-900	99

605	Reduced Regional Cerebral Blood Flow Relates to Poorer Cognition in Older Adults With Type 2 Diabetes. 2018 , 10, 270	49
604	Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. 2018 , 60, 13-25	7
603	Alzheimer's disease as a metabolic disorder. 2018 , 25, D403	4
602	The Early Events That Initiate β Amyloid Aggregation in Alzheimer's Disease. 2018 , 10, 359	47
601	Signaling Mechanisms of Selective PPAR Modulators in Alzheimer's Disease. 2018 , 2018, 2010675	34
600	Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review. 2018 , 19, 522-602	41
599	Insulin Resistance in Alzheimer's Disease. 2018 , 12, 830	94
598	Inflammation as a central mechanism in Alzheimer's disease. 2018 , 4, 575-590	641
597	Potential therapeutics of Alzheimer's diseases: New insights into the neuroprotective role of trehalose-conjugated beta sheet breaker peptides. 2018 , 110, e24083	8
596	Characterization of Impaired Cerebrovascular Structure in APP/PS1 Mouse Brains. 2018 , 385, 246-254	21
595	A review of brain insulin signaling in mood disorders: From biomarker to clinical target. 2018 , 92, 7-15	14
594	Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. 2018 , 281, 139-177	228
593	The effect of celastrol on learning and memory in diabetic rats after sevoflurane inhalation. 2018 , 14, 370-380	10
592	Aging and Alzheimer's disease: Comparison and associations from molecular to system level. 2018 , 17, e12802	87
591	Type 1 Diabetes and Epigenetics. 2018 , 187-205	0
590	The Role of Insulin Resistance and Signaling in Dementia. 2018 , 143-168	
589	Insulin-Like Growth Factor Binding Protein 2 Is Associated With Biomarkers of Alzheimer's Disease Pathology and Shows Differential Expression in Transgenic Mice. 2018 , 12, 476	12
588	Defensive effect of microRNA-200b/c against amyloid-beta peptide-induced toxicity in Alzheimer's disease models. 2018 , 13, e0196929	48

587	The serum metabolomics signature of type 2 diabetes is obscured in Alzheimer's disease. 2018 , 314, E584-E596	9
586	'Evolutionary medicine' perspectives on Alzheimer's Disease: Review and new directions. 2018 , 47, 140-148	16
585	Streptozotocin-induced β cell damage, high fat diet, and metformin administration regulate Hes3 expression in the adult mouse brain. 2018 , 8, 11335	3
584	Mechanisms of Risk Reduction in the Clinical Practice of Alzheimer's Disease Prevention. 2018 , 10, 96	19
583	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. 2018 , 12, 37	77
582	Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review. 2018 , 12, 215	50
581	Suppressor of Cytokine Signaling 3: Emerging Role Linking Central Insulin Resistance and Alzheimer's Disease. 2018 , 12, 417	15
580	Glutamine Synthetase: Localization Dictates Outcome. 2018 , 9,	25
579	Biliverdin reductase-A impairment links brain insulin resistance with increased A β production in an animal model of aging: Implications for Alzheimer disease. 2018 , 1864, 3181-3194	28
578	The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia. 2018 , 11,	32
577	iPSC-derived familial Alzheimer's PSEN2 cholinergic neurons exhibit mutation-dependent molecular pathology corrected by insulin signaling. 2018 , 13, 33	25
576	Pigment Epithelium-Derived Factor Plays a Role in Alzheimer's Disease by Negatively Regulating A β 2. 2018 , 15, 728-741	9
575	Altered Insulin/Insulin-Like Growth Factor Signaling in a Comorbid Rat model of Ischemia and β Amyloid Toxicity. 2018 , 8, 5136	15
574	Pin1 Modulation in Physiological Status and Neurodegeneration. Any Contribution to the Pathogenesis of Type 3 Diabetes?. 2018 , 19,	4
573	NO-Dependent Akt Inactivation by S-Nitrosylation as a Possible Mechanism of STZ-Induced Neuronal Insulin Resistance. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 1427-1443	4-3 6
572	Diet and Brain Health: Which Role for Polyphenols?. 2018 , 24, 227-238	33
571	Interactions Between Age, Diet, and Insulin and Their Effect on Cognition. 2018 , 223-238	
570	Glucose, Insulin, and Human Brain Aging. 2018 , 889-898	1

569	SIRT3 activator Honokiol attenuates β Amyloid by modulating amyloidogenic pathway. 2018 , 13, e0190350	42
568	Tissue-Specific Upregulation of Drosophila Insulin Receptor (InR) Mitigates Poly(Q)-Mediated Neurotoxicity by Restoration of Cellular Transcription Machinery. 2019 , 56, 1310-1329	7
567	Neuroactive Steroids and Sex-Dimorphic Nervous Damage Induced by Diabetes Mellitus. 2019 , 39, 493-502	5
566	The Medial Septum Is Insulin Resistant in the AD Presymptomatic Phase: Rescue by Nerve Growth Factor-Driven IRS Activation. 2019 , 56, 535-552	11
565	Ribosylation-Derived Advanced Glycation End Products Induce Tau Hyperphosphorylation Through Brain-Derived Neurotrophic Factor Reduction. <i>Journal of Alzheimer's Disease</i> , 2019 , 71, 291-305	4-3 12
564	Protective effect of ISO-1 against advanced glycation end product aggravation of PC12 cell injury induced by A β -40. 2019 , 20, 2135-2142	5
563	Deciphering the Link Between Hyperhomocysteinemia and Ceramide Metabolism in Alzheimer-Type Neurodegeneration. 2019 , 10, 807	15
562	Neurometabolic Evidence Supporting the Hypothesis of Increased Incidence of Type 3 Diabetes Mellitus in the 21st Century. 2019 , 2019, 1435276	15
561	Potential synaptic plasticity-based Shenzhiling oral liquid for a SAD Mouse Model. 2019 , 9, e01385	3
560	Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. 2019 , 15, 501-518	322
559	Adenovirus 36 improves glycemic control and markers of Alzheimer's disease pathogenesis. 2019 , 1865, 165531	5
558	Hypothesis and Theory: Circulating Alzheimer's-Related Biomarkers in Type 2 Diabetes. Insight From the Goto-Kakizaki Rat. 2019 , 10, 649	6
557	Chronic oleoylethanolamide treatment attenuates diabetes-induced mice encephalopathy by triggering peroxisome proliferator-activated receptor alpha in the hippocampus. 2019 , 129, 104501	6
556	Insulin-Mediated Changes in Tau Hyperphosphorylation and Autophagy in a Model of Tauopathy and Neuroblastoma Cells. 2019 , 13, 801	8
555	Inhibition of PDE5 attenuates streptozotocin-induced neuroinflammation and tau hyperphosphorylation in a streptozotocin-treated rat model. 2019 , 1722, 146344	4
554	A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer's Disease in transgenic mice. 2019 , 372, 112015	7
553	Higher GABA concentration in the medial prefrontal cortex of Type 2 diabetes patients is associated with episodic memory dysfunction. 2019 , 40, 4287-4295	11
552	Methamphetamine exposure upregulates the amyloid precursor protein and hyperphosphorylated tau expression: The roles of insulin signaling in SH-SY5Y cell line. 2019 , 44, 493-503	5

551	Consequences of Metabolic Disruption in Alzheimer's Disease Pathology. 2019 , 16, 600-610	24
550	Altered Insulin Signaling in Alzheimer's Disease Brain - Special Emphasis on PI3K-Akt Pathway. 2019 , 13, 629	114
549	Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-1 in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice. 2019 , 99, 103390	22
548	Body Shape and Alzheimer's Disease: A Mendelian Randomization Analysis. 2019 , 13, 1084	6
547	The Brain at Risk. 2019 ,	1
546	Liraglutide Treatment Ameliorates Neurotoxicity Induced by Stable Silencing of Pin1. 2019 , 20,	6
545	PPAR and Cognitive Performance. 2019 , 20,	17
544	. 2019 ,	0
543	Dual-specificity tyrosine phosphorylation-regulated kinase 1A ameliorates insulin resistance in neurons by up-regulating IRS-1 expression. 2019 , 294, 20164-20176	5
542	Oleanolic Acid Exerts a Neuroprotective Effect Against Microglial Cell Activation by Modulating Cytokine Release and Antioxidant Defense Systems. 2019 , 9,	20
541	The Novel Perspectives of Adipokines on Brain Health. 2019 , 20,	32
540	Insulin Inhibits A β 2 Aggregation and Prevents A β 2-Induced Membrane Disruption. 2019 , 58, 4519-4529	8
539	Loss of insulin-like growth factor-1 signaling in astrocytes disrupts glutamate handling. 2019 , 151, 689-702	7
538	Acute exercise and brain BACE1 protein content: a time course study. 2019 , 7, e14084	9
537	Rediscovering an old friend: a role for insulin growth factor-2 in reducing neurodegeneration, decreasing amyloid beta, and improving memory. 2019 , 31, 925-927	1
536	Brain Insulin Resistance and Hippocampal Plasticity: Mechanisms and Biomarkers of Cognitive Decline. 2019 , 13, 788	67
535	The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer's Dementia. 2019 , 11, 236	25
534	MicroRNA 7 Impairs Insulin Signaling and Regulates A β Levels through Posttranscriptional Regulation of the Insulin Receptor Substrate 2, Insulin Receptor, Insulin-Degrading Enzyme, and Liver X Receptor Pathway. 2019 , 39,	24

533	Developing Trojan horses to induce, diagnose and suppress Alzheimer's pathology. 2019 , 149, 104471	6
532	Redox chemistry and biological activities of chromium(III) complexes. 2019 , 281-321	2
531	Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology. 2019 , 56, 5815-5834	22
530	Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy. 2019 , 176, 3447-3463	73
529	Regulation of Memory Function by Feeding-Relevant Biological Systems: Following the Breadcrumbs to the Hippocampus. 2019 , 12, 101	22
528	Altered expression of insulin-degrading enzyme and regulator of calcineurin in the rat intracerebral streptozotocin model and human apolipoprotein E- ϵ -associated Alzheimer's disease. 2019 , 11, 392-404	8
527	Protective Effect of Caffeic Acid against Alzheimer's Disease Pathogenesis via Modulating Cerebral Insulin Signaling, β Amyloid Accumulation, and Synaptic Plasticity in Hyperinsulinemic Rats. 2019 , 67, 7684-7693	24
526	Glycosylation profiling of selected proteins in cerebrospinal fluid from Alzheimer's disease and healthy subjects. 2019 , 11, 3331-3340	4
525	A Perspective to the Correlation Between Brain Insulin Resistance and Alzheimer: Medicinal Chemistry Approach. 2019 , 15, 255-258	2
524	Shared Pathological Mechanisms Between Diabetes Mellitus and Neurodegenerative Diseases. 2019 , 5, 219-231	2
523	Stable Co-Cultivation of the Moss <i>Physcomitrella patens</i> with Human Cells in vitro as a New Approach to Support Metabolism of Diseased Alzheimer Cells. <i>Journal of Alzheimer's Disease</i> , 2019 , 70, 75-89	4-3 1
522	Vanadyl acetylacetonate attenuates A β pathogenesis in APP/PS1 transgenic mice depending on the intervention stage. 2019 , 43, 17588-17594	3
521	Combined Effect of Fatty Diet and Cognitive Decline on Brain Metabolism, Food Intake, Body Weight, and Counteraction by Intranasal Insulin Therapy in 3 \times Tg Mice. 2019 , 13, 188	8
520	The Role of Insulin Resistance and Protein O-GlcNAcylation in Neurodegeneration. 2019 , 13, 473	13
519	Insulin and Autophagy in Neurodegeneration. 2019 , 13, 491	24
518	Unraveling the complex interplay of immunometabolic systems that contribute to the neuroprogression of psychiatric disorders. 2019 , 32, 111-121	5
517	O-GlcNAcylation of Amyloid- β Protein Precursor by Insulin Signaling Reduces Amyloid- β Production. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 1195-1211	4-3 8
516	Pathological and cognitive changes in patients with type 2 diabetes mellitus and comorbid MCI and protective hypoglycemic therapies: a narrative review. 2019 , 30, 757-770	1

515	Icariin Inhibits AGE-Induced Injury in PC12 Cells by Directly Targeting Apoptosis Regulator Bax. 2019 , 2019, 7940808	15
514	The Full Spectrum of Alzheimer's Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes. 2019 , 1128, 45-83	21
513	Molecular Connection Between Diabetes and Dementia. 2019 , 1128, 103-131	7
512	The Role of Insulin-Like Growth Factors and Insulin-Like Growth Factor-Binding Proteins in the Nervous System. 2019 , 12, 1178626419842176	52
511	Diabetes Mellitus. 2019 ,	
510	Crucial players in Alzheimer's disease and diabetes mellitus: Friends or foes?. 2019 , 181, 7-21	16
509	Altered Brain Expression of Insulin and Insulin-Like Growth Factors in Frontotemporal Lobar Degeneration: Another Degenerative Disease Linked to Dysregulation of Insulin Metabolic Pathways. 2019 , 11, 1759091419839515	6
508	Prevention and Treatment of Alzheimer's Disease: Biological Mechanisms of Exercise. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 311-338	4-3 24
507	Interplay between Alzheimer's disease and global glucose metabolism revealed by the metabolic profile alterations of pancreatic tissue and serum in APP/PS1 transgenic mice. 2019 , 40, 1259-1268	10
506	The Link Between Exercise and Mediation of Alzheimer's Disease and Neurodegenerative Diseases. 2019 , 371-390	
505	Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases). 2019 , 391-442	1
504	The Link Between Diabetes, Glucose Control, and Alzheimer's Disease and Neurodegenerative Diseases. 2019 , 89-115	
503	Curcumin Ameliorates the Impaired Insulin Signaling Involved in the Pathogenesis of Alzheimer's Disease in Rats. 2019 , 3, 59-70	12
502	Comprehensive review on the interaction between natural compounds and brain receptors: Benefits and toxicity. 2019 , 174, 87-115	21
501	The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo. 2019 , 16, 281-292	3
500	Biological Hallmarks of Cancer in Alzheimer's Disease. 2019 , 56, 7173-7187	20
499	ApoE4: an emerging therapeutic target for Alzheimer's disease. 2019 , 17, 64	169
498	Outcomes and clinical implications of intranasal insulin administration to the central nervous system. 2019 , 317, 180-190	23

497	Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer's Disease. 2019 , 11, 20		17
496	Dietary Fat Intake and Cognitive Function among Older Populations: A Systematic Review and Meta-Analysis. 2019 , 6, 204-211		12
495	Cross-disease analysis of Alzheimer's disease and type-2 Diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases. 2019 , 9, 3965		41
494	Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine. 2019 , 199, 173-187		48
493	Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease. 2019 , 14, 15		46
492	Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease. 2019 , 11, 88		41
491	Vildagliptine protects SH-SY5Y human neuron-like cells from A β -42 induced toxicity, in vitro. 2019 , 71, 635-646		1
490	Understanding the link between insulin resistance and Alzheimer's disease: Insights from animal models. 2019 , 316, 1-11		16
489	GLP-1's role in neuroprotection: a systematic review. 2019 , 33, 734-819		32
488	Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients. 2019 , 92, e1344-e1353		6
487	Late Effects. 2019 , 496-554		
486	Impaired Glucose Tolerance and Reduced Plasma Insulin Precede Decreased AKT Phosphorylation and GLUT3 Translocation in the Hippocampus of Old 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 809-837	4.3	18
485	Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease. 2019 , 125, 176-189		38
484	The Link Between Tau and Insulin Signaling: Implications for Alzheimer's Disease and Other Tauopathies. 2019 , 13, 17		34
483	Bioactive Metabolites Isolated from Microorganisms for Healthcare: Types and Delivery Routes. 2019 , 75-97		1
482	Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 537-550	4.3	5
481	Insulin Resistance and Oxidative Stress in the Brain: What's New?. 2019 , 20,		91
480	Early-Stage Alzheimer's Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 657-668	4.3	25

479	Insulin signaling in the hippocampus and amygdala regulates metabolism and neurobehavior. 2019 , 116, 6379-6384	60
478	Focus on the Correlations between Alzheimer's Disease and Type 2 Diabetes. 2019 , 19, 571-579	10
477	Delirium Superimposed Upon Dementia. 2019 , 20, 1382-1383	3
476	Diabetes, a Contemporary Risk for Parkinson's Disease: Epidemiological and Cellular Evidences. 2019 , 11, 302	31
475	Systemic and central nervous system metabolic alterations in Alzheimer's disease. 2019 , 11, 93	57
474	Oxidative Stress, DNA Damage and Repair Pathways in Patients with Type 2 Diabetes Mellitus. 2019 ,	1
473	Natural Compounds as Beneficial Antioxidant Agents in Neurodegenerative Disorders: A Focus on Alzheimer's Disease. 2019 , 8,	35
472	c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments. 2019 , 97, 1723-1733	7
471	The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimer's Disease. 2018 , 12, 1027	71
470	Broadening the definition of brain insulin resistance in aging and Alzheimer's disease. 2019 , 313, 79-87	22
469	Timing Matters: Circadian Effects on Energy Homeostasis and Alzheimer's Disease. 2019 , 30, 132-143	6
468	Enhanced intranasal insulin delivery by formulations and tumor protein-derived protein transduction domain as an absorption enhancer. 2019 , 294, 226-236	11
467	Intranasal insulin activates Akt2 signaling pathway in the hippocampus of wild-type but not in APP/PS1 Alzheimer model mice. 2019 , 75, 98-108	17
466	Sitagliptin protects the cognition function of the Alzheimer's disease mice through activating glucagon-like peptide-1 and BDNF-TrkB signalings. 2019 , 696, 184-190	18
465	Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies. 2019 , 174, 53-89	137
464	Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by A β peptides in animal model of Alzheimer's disease. 2019 , 110, 47-58	53
463	Elevated Membrane Cholesterol Disrupts Lysosomal Degradation to Induce β Amyloid Accumulation: The Potential Mechanism Underlying Augmentation of β Amyloid Pathology by Type 2 Diabetes Mellitus. 2019 , 189, 391-404	2
462	Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues. 2019 , 316, E106-E120	12

461	Aberrant Neuronal Cell Cycle Re-Entry: The Pathological Confluence of Alzheimer's Disease and Brain Insulin Resistance, and Its Relation to Cancer. <i>Journal of Alzheimer's Disease</i> , 2019 , 67, 1-11	4-3	11
460	Cannabinoid Receptor Type 1 Agonist ACEA Improves Cognitive Deficit on STZ-Induced Neurotoxicity Through Apoptosis Pathway and NO Modulation. 2019 , 35, 516-529		11
459	Insulin growth factor 2 (IGF2) as an emergent target in psychiatric and neurological disorders. Review. 2019 , 149, 1-13		18
458	Diabetes and Alzheimer's Disease: A Link not as Simple as it Seems. 2019 , 44, 1271-1278		26
457	Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases. 2019 , 33, 209-223		32
456	GluT4: A central player in hippocampal memory and brain insulin resistance. 2020 , 323, 113076		32
455	Intranasal insulin treatment modulates the neurotropic, inflammatory, and oxidant mechanisms in the cortex and hippocampus in a low-grade inflammation model. 2020 , 123, 170175		6
454	Cognitive dysfunction: A growing link between diabetes and Alzheimer's disease. 2020 , 81, 144-164		22
453	Disparate Central and Peripheral Effects of Circulating IGF-1 Deficiency on Tissue Mitochondrial Function. 2020 , 57, 1317-1331		9
452	Silibinin ameliorates STZ-induced impairment of memory and learning by up-regulating insulin signaling pathway and attenuating apoptosis. 2020 , 213, 112689		19
451	Oridonin prevents insulin resistance-mediated cognitive disorder through PTEN/Akt pathway and autophagy in minimal hepatic encephalopathy. 2020 , 24, 61-78		6
450	Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment. 2019 , 21,		11
449	Lack of insulin resistance in response to streptozotocin treatment in neuronal SH-SY5Y cell line. 2020 , 127, 71-80		3
448	O-GlcNAcylation as a Therapeutic Target for Alzheimer's Disease. 2020 , 22, 171-193		16
447	Spontaneous ruptured aortic plaque and injuries: insights for aging and acute aortic syndrome from non-obstructive general angioscopy. 2020 , 75, 344-351		3
446	Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators. 2020 , 27, 736-750		21
445	The protective role of pre-morbid type 2 diabetes in patients with amyotrophic lateral sclerosis: a center-based survey in China. 2020 , 21, 209-215		4
444	GIP has neuroprotective effects in Alzheimer and Parkinson's disease models. 2020 , 125, 170184		22

443	Chromium picolinate attenuates cognitive deficit in ICV-STZ rat paradigm of sporadic Alzheimer's-like dementia via targeting neuroinflammatory and IRS-1/PI3K/AKT/GSK-3 β pathway. 2020 , 28, 385-400	18
442	Okra polysaccharides can reverse the metabolic disorder induced by high-fat diet and cognitive function injury in A β mice. 2020 , 130, 110802	5
441	Neuroendocrine Disturbances in Neurodegenerative Disorders: A Scoping Review. 2020 , 61, 105-115	7
440	Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of A β Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model. 2020 , 57, 1473-1483	10
439	A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice. 2020 , 118, 104640	7
438	The correlation of serum adiponectin and insulin resistance with the presence and severity of dementia in non-obese Alzheimer's patients. 2020 , 40, 376-382	2
437	Dysfunctional proteins in neuropsychiatric disorders: From neurodegeneration to autism spectrum disorders. 2020 , 141, 104853	4
436	Metabolic Dysregulation Contributes to the Progression of Alzheimer's Disease. 2020 , 14, 530219	27
435	The Role of Bilirubin and the Other "Yellow Players" in Neurodegenerative Diseases. 2020 , 9,	3
434	Microglial Immunometabolism in Alzheimer's Disease. 2020 , 14, 563446	9
433	Involvement of TGF- β and Autophagy Pathways in Pathogenesis of Diabetes: A Comprehensive Review on Biological and Pharmacological Insights. 2020 , 11, 498758	6
432	Unwinding Complexities of Diabetic Alzheimer by Potent Novel Molecules. 2020 , 35, 1533317520937542	8
431	Tankyrase inhibition augments neuronal insulin sensitivity and glucose uptake via AMPK-AS160 mediated pathway. 2020 , 141, 104854	1
430	Insulin signaling as a therapeutic target in Alzheimer's disease: Efficacy of apomorphine. 2020 , 8, 146-154	6
429	Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions. 2020 , 14, 670	17
428	Altered Brain Adiponectin Receptor Expression in the 5XFAD Mouse Model of Alzheimer's Disease. 2020 , 13,	2
427	Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale. 2020 , 4, 185-215	25
426	c-Jun N-Terminal Kinases in Alzheimer's Disease: A Possible Target for the Modulation of the Earliest Alterations. <i>Journal of Alzheimer's Disease</i> , 2021 , 82, S127-S139	4-3 3

425	A study on the determination of two related aminothiols in the brain of diabetes rats by HPLC-ECD. 2020 , 43, 725-732	0
424	The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases. 2020 , 154, 345-391	10
423	Examining the causal mediating role of brain pathology on the relationship between diabetes and cognitive impairment: the Cardiovascular Health Study. 2020 , 183, 1705-1726	0
422	Brain insulin resistance impairs hippocampal plasticity. 2020 , 114, 281-306	7
421	Endosomal-lysosomal dysfunction in metabolic diseases and Alzheimer's disease. 2020 , 154, 303-324	1
420	The mitochondrial hypothesis: Dysfunction, bioenergetic defects, and the metabolic link to Alzheimer's disease. 2020 , 154, 207-233	15
419	Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. 2020 , 19, 758-766	126
418	Healthy brain, healthy life: a review of diet and exercise interventions to promote brain health and reduce Alzheimer's disease risk. 2020 , 45, 1055-1065	20
417	Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones. 2020 , 155, 37-64	10
416	Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid- β Cascade in Alzheimer's Disease. 2020 , 21,	15
415	Clusterin as a Potential Biomarker of Obesity-Related Alzheimer's Disease Risk. 2020 , 15, 1177271920964108	1
414	Alogliptin reversed hippocampal insulin resistance in an amyloid-beta fibrils induced animal model of Alzheimer's disease. 2020 , 889, 173522	5
413	Sulforaphene Ameliorates Neuroinflammation and Hyperphosphorylated Tau Protein via Regulating the PI3K/Akt/GSK-3 Pathway in Experimental Models of Alzheimer's Disease. 2020 , 2020, 4754195	23
412	Gut Microbiota and Dysbiosis in Alzheimer's Disease: Implications for Pathogenesis and Treatment. 2020 , 57, 5026-5043	64
411	Cellular Signaling and Anti-Apoptotic Effects of Prolactin-Releasing Peptide and Its Analog on SH-SY5Y Cells. 2020 , 21,	1
410	Adiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimer's Disease. 2020 , 21,	10
409	Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease. 2020 , 14, 614828	7
408	Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review. 2020 , 11, 560375	15

407	Effect of Peripheral Insulin Administration on Phosphorylation of Tau in the Brain. <i>Journal of Alzheimer's Disease</i> , 2020 , 75, 1377-1390	4-3
406	Biotin, coenzyme Q10, and their combination ameliorate aluminium chloride-induced Alzheimer's disease via attenuating neuroinflammation and improving brain insulin signaling. 2020 , 34, e22519	8
405	Adding value to polyvinylpyrrolidone winery residue: A resource of polyphenols with neuroprotective effects and ability to modulate type 2 diabetes-relevant enzymes. 2020 , 329, 127168	5
404	Patients with Alzheimer's Disease Have Increased Levels of Insulin-like Growth Factor-I in Serum but not in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2020 , 75, 289-298	4-3 5
403	Interleukin-6 Treatment Results in GLUT4 Translocation and AMPK Phosphorylation in Neuronal SH-SY5Y Cells. 2020 , 9,	8
402	Sildenafil for the Treatment of Alzheimer's Disease: A Systematic Review. 2020 , 4, 91-106	12
401	Insulin resistance and Alzheimer's disease. 2020 , 249-292	0
400	Yeast β -glucan alleviates cognitive deficit by regulating gut microbiota and metabolites in A β -induced AD-like mice. 2020 , 161, 258-270	31
399	Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function. 2020 , 88, 513-525	24
398	Crosstalk between obesity, diabetes, and alzheimer's disease: Introducing quercetin as an effective triple herbal medicine. 2020 , 62, 101095	32
397	Plasma Clusterin as a Potential Link Between Diabetes and Alzheimer Disease. 2020 , 105,	5
396	Brain insulin resistance: role in neurodegenerative disease and potential for targeting. 2020 , 29, 333-348	44
395	Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity. 2020 , 21,	13
394	Neurodegeneration in Alzheimer's disease and glaucoma: overlaps and missing links. 2020 , 34, 1546-1553	14
393	SCR-1693 inhibits tau phosphorylation and improves insulin resistance associated cognitive deficits. 2020 , 168, 108027	2
392	Insulin mediated novel therapies for the treatment of Alzheimer's disease. 2020 , 249, 117540	22
391	Alzheimer's disease: A need for personalized therapeutic approaches. 2020 , 81, 141-143	3
390	Mini Review: Opposing Pathologies in Cancer and Alzheimer's Disease: Does the PI3K/Akt Pathway Provide Clues?. 2020 , 11, 403	8

389	Intermittent fasting promotes adult hippocampal neuronal differentiation by activating GSK-3β in 3xTg-AD mice. 2020 , 155, 697-713	3
388	Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer's disease. 2020 , 135, 104707	37
387	Effect of amyloid toxicity or chronic cerebral hypoperfusion on brain insulin resistance in a rat model with intracerebroventricular streptozotocin. 2020 , 158, 40-50	3
386	Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention. 2020 , 32, 1188-1236	27
385	Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review. 2020 , 18, 125-151	17
384	ApoE and cerebral insulin: Trafficking, receptors, and resistance. 2020 , 137, 104755	20
383	Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. 2020 , 137, 104772	23
382	The novel GLP-1/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD. 2020 , 10, e01505	21
381	Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease. 2020 , 81, 194-205	9
380	Interaction of opioid with insulin/IGFs signaling in Alzheimer's disease. 2020 , 70, 819-834	2
379	Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports. 2020 , 11, 315	3
378	Insulin resistance, diabetes, and metabolic syndrome. 2020 , 71-112	1
377	Role of Insulin Resistance in the Alzheimer's Disease Progression. 2020 , 45, 1481-1491	20
376	Electroacupuncture improves cognitive deficits and insulin resistance in an OLETF rat model of Al/D-gal induced aging model via the PI3K/Akt signaling pathway. 2020 , 1740, 146834	3
375	Brain Metabolism Alterations in Type 2 Diabetes: What Did We Learn From Diet-Induced Diabetes Models?. 2020 , 14, 229	24
374	Mitochondria-Targeted Small Peptide, SS31 Ameliorates Diabetes Induced Mitochondrial Dynamics in Male TallyHO/JngJ Mice. 2021 , 58, 795-808	10
373	Acteoside-improved streptozotocin-induced learning and memory impairment by upregulating hippocampal insulin, glucose transport, and energy metabolism. 2021 , 35, 392-403	5
372	Functions of amyloid precursor protein in metabolic diseases. 2021 , 115, 154454	10

371	Mini-review: Role of the PI3K/Akt pathway and tyrosine phosphatases in Alzheimer's disease susceptibility. 2021 , 85, 1-6	7
370	Human gut microbiota <i>Agathobaculum butyriciproducens</i> improves cognitive impairment in LPS-induced and APP/PS1 mouse models of Alzheimer's disease. 2021 , 86, 96-108	10
369	AMPK: A bridge between diabetes mellitus and Alzheimer's disease. 2021 , 400, 113043	18
368	Intranasal Insulin for Alzheimer's Disease. 2021 , 35, 21-37	19
367	Targeting Insulin Resistance to Treat Cognitive Dysfunction. 2021 , 58, 2672-2691	6
366	Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.. 2021 , 2, 100022	0
365	Growth Hormone and Neuronal Hemoglobin in the Brain-Roles in Neuroprotection and Neurodegenerative Diseases. 2020 , 11, 606089	5
364	Molecular mechanisms in Alzheimer's disease and the impact of physical exercise with advancements in therapeutic approaches. 2021 , 8, 357-389	2
363	Obesogenic Diets Cause Alterations on Proteins and Theirs Post-Translational Modifications in Mouse Brains. 2021 , 14, 11786388211012405	1
362	The Pathogenesis Mechanism, Structure Properties, Potential Drugs and Therapeutic Nanoparticles against the Small Oligomers of Amyloid- β 2021 , 21, 151-167	2
361	Experimental Approach to Alzheimer's Disease with Emphasis on Insulin Resistance in the Brain. 2021 , 1-52	0
360	Suppression of neuronal cholesterol biosynthesis impairs brain functions through insulin-like growth factor I-Akt signaling. 2021 , 17, 3702-3716	1
359	Exploring the New Horizon of AdipoQ in Obesity-Related Alzheimer's Dementia. 2020 , 11, 567678	3
358	Alzheimer's Disease and Protein Kinases. 2021 , 1275, 285-321	5
357	Circadian changes in Alzheimer's disease: Neurobiology, clinical problems, and therapeutic opportunities. 2021 , 179, 285-300	3
356	Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease. 2021 , 13, 51	36
355	Expression of glucose transporters in human neurodegenerative diseases. 2021 , 540, 8-15	7
354	Insulin-Like Growth Factor 2 As a Possible Neuroprotective Agent and Memory Enhancer-Its Comparative Expression, Processing and Signaling in Mammalian CNS. 2021 , 22,	4

353	Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome. 2021 , 12, 612496	2
352	A ketogenic diet differentially affects neuron and astrocyte transcription. 2021 , 157, 1930-1945	1
351	Metabolic disorder in Alzheimer's disease. 2021 , 36, 781-813	3
350	"Cell Membrane Theory of Senescence" and the Role of Bioactive Lipids in Aging, and Aging Associated Diseases and Their Therapeutic Implications. 2021 , 11,	14
349	Dissecting Sex-Related Cognition between Alzheimer's Disease and Diabetes: From Molecular Mechanisms to Potential Therapeutic Strategies. 2021 , 2021, 4572471	3
348	A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glutathione in Amnesic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease. 2021 , 38, 407-415	6
347	Alzheimer's Disease: Pathogenesis and Therapeutic interventions. 2021 ,	3
346	Risk of Alzheimer's disease and environmental bisphenol A exposure. 2021 , 25, 36-41	0
345	Role of insulin receptor substrate-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer's disease. 2021 , 11, 179	2
344	Brain Insulin Resistance: Focus on Insulin Receptor-Mitochondria Interactions. 2021 , 11,	4
343	Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer's disease. 2021 , 33, e12959	9
342	Therapies for Alzheimer's disease: a metabolic perspective. 2021 , 132, 162-172	3
341	Defining early changes in Alzheimer's disease from RNA sequencing of brain regions differentially affected by pathology. 2021 , 11, 4865	6
340	Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome. 2021 , 165, 152-170	16
339	Inflammation and Insulin Resistance as Risk Factors and Potential Therapeutic Targets for Alzheimer's Disease. 2021 , 15, 653651	6
338	The link between nutrition and Alzheimer's disease: from prevention to treatment. 2021 , 11, 155-166	3
337	Resveratrol, Metabolic Dysregulation, and Alzheimer's Disease: Considerations for Neurodegenerative Disease. 2021 , 22,	6
336	The brain as an insulin-sensitive metabolic organ. 2021 , 52, 101234	12

335	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. 2021 , 11,		7
334	A New Approach to Model Sporadic Alzheimer's Disease by Intracerebroventricular Streptozotocin Injection in APP/PS1 Mice. 2021 , 58, 3692-3711		2
333	Glycolytic Metabolism, Brain Resilience, and Alzheimer's Disease. 2021 , 15, 662242		11
332	Insulin Resistance and Diabetes Mellitus in Alzheimer's Disease. 2021 , 10,		10
331	Alzheimer's disease and gut microbiota: does trimethylamine N-oxide (TMAO) play a role?. 2021 ,		3
330	A Tau-Driven Adverse Outcome Pathway Blueprint Toward Memory Loss in Sporadic (Late-Onset) Alzheimer's Disease with Plausible Molecular Initiating Event Plug-Ins for Environmental Neurotoxicants. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 459-485	4-3	3
329	Estradiol selectively regulates metabolic substrates across memory systems in models of menopause. 2021 , 24, 366-372		2
328	Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. 2021 ,		11
327	Intranasal insulin and orexins to treat age-related cognitive decline. 2021 , 234, 113370		7
326	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. <i>Journal of Alzheimer's Disease</i> , 2021 , 82, 71-105	4-3	7
325	Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine. 2021 , 22,		5
324	Protective effects of a mitochondria-targeted small peptide SS31 against hyperglycemia-induced mitochondrial abnormalities in the liver tissues of diabetic mice, Tallyho/JngJ mice. 2021 , 58, 49-58		7
323	Neurotrophic signaling deficiency exacerbates environmental risks for Alzheimer's disease pathogenesis. 2021 , 118,		3
322	Alzheimer's disease and diet: the missing link?. 2021 , 17, 92-93		
321	The Involvement of Insulin-Like Growth Factor 1 and Nerve Growth Factor in Alzheimer's Disease-Like Pathology and Survival Role of the Mix of Embryonic Proteoglycans: Electrophysiological Fingerprint, Structural Changes and Regulatory Effects on Neurotrophins. 2021 , 22,		2
320	Activation of PI3K/Akt Signaling Pathway in Rat Hypothalamus Induced by an Acute Oral Administration of D-Pinitol. 2021 , 13,		2
319	Reassessment of Pioglitazone for Alzheimer's Disease. 2021 , 15, 666958		5
318	Transcriptomic and Genetic Associations between Alzheimer's Disease, Parkinson's Disease, and Cancer. 2021 , 13,		6

317	The S6k/4E-BP mediated growth promoting sub-pathway of insulin signalling cascade is essential to restrict pathogenesis of poly(Q) disorders in <i>Drosophila</i> . 2021 , 275, 119358	2
316	The cerebral hypometabolism model of Alzheimer's disease explored: can a ketogenic diet improve cognition in Alzheimer's disease? A review of the literature. 2021 , 17, 95-103	
315	Research on the Glial-Lymphatic System and Its Relationship With Alzheimer's Disease. 2021 , 15, 605586	0
314	Imipramine alleviates memory impairment and hippocampal apoptosis in STZ-induced sporadic Alzheimer's rat model: Possible contribution of MAPKs and insulin signaling. 2021 , 408, 113260	0
313	Peganum harmala enhanced GLP-1 and restored insulin signaling to alleviate Aβ-induced Alzheimer-like pathology model. 2021 , 11, 12040	4
312	Metabolic Syndrome: Is It Time to Add the Central Nervous System?. 2021 , 13,	3
311	Brain Glucose Transporters: Role in Pathogenesis and Potential Targets for the Treatment of Alzheimer's Disease. 2021 , 22,	2
310	Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms. 2021 , 15, 687157	9
309	Mitostasis, Calcium and Free Radicals in Health, Aging and Neurodegeneration. 2021 , 11,	11
308	Insulin-like growth factor 1 gene transfer for sporadic Alzheimer's disease: New evidence for trophic factor mediated hippocampal neuronal and synaptic recovery-based behavior improvement. 2021 , 31, 1137-1153	1
307	Effects of the Clock Modulator Nobiletin on Circadian Rhythms and Pathophysiology in Female Mice of an Alzheimer's Disease Model. 2021 , 11,	4
306	Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. 2021 , 16, 44	21
305	Enhancement of Insulin/PI3K/Akt Signaling Pathway and Modulation of Gut Microbiome by Probiotics Fermentation Technology, a Kefir Grain Product, in Sporadic Alzheimer's Disease Model in Mice. 2021 , 12, 666502	3
304	Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer's disease in metabolically stressed APP ^{swe} /PS1 ^{dE9} mice. 2021 , 11, 141	2
303	Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer's disease by meta-analysis and adaptive boosting ensemble learning. 2021 , 13, 126	8
302	A Computational Exploration of the Molecular Network Associated to Neuroinflammation in Alzheimer's Disease. 2021 , 12, 630003	1
301	Diabetes and Alzheimer's Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path?. 2021 , 10,	6
300	Decreased Levels of Insulin-Like Growth Factor-1 Are Associated with Alzheimer's Disease: A Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2021 , 82, 1357-1367	4-3 1

299	From obesity to Alzheimer's disease through insulin resistance. 2021 , 35, 108026		7
298	Oral semaglutide in the management of type 2 DM: Clinical status and comparative analysis. 2021 ,		
297	Effect of hydro-alcoholic extract of centella asiatica on streptozotocin induced memory dysfunction in adult zebrafish. 2021 , 2, 100059		0
296	Effects of apolipoprotein E isoform, sex, and diet on insulin BBB pharmacokinetics in mice. 2021 , 11, 18636		0
295	Insulin-degrading enzyme: an ally against metabolic and neurodegenerative diseases. 2021 , 255, 346-361		8
294	Large-scale proteome analysis of CSF implicates altered glucose metabolism in Alzheimer's disease.		0
293	Cognitive Deficits in Type-1 Diabetes: Aspects of Glucose, Cerebrovascular and Amyloid Involvement. 2021 , 38, 1477-1484		0
292	Metabolic Disturbances Induced by Sleep Restriction as Potential Triggers for Alzheimer's Disease. 2021 , 15, 722523		0
291	Insulin and Insulin Resistance in Alzheimer's Disease. 2021 , 22,		7
290	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. 2021 , 72, 101462		5
289	Alzheimer's Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort. <i>Journal of Alzheimer's Disease</i> , 2021 , 83, 1303-1312	4.3	1
288	Differential involvement of insulin receptor substrate (IRS)-1 and IRS-2 in brain insulin signaling is associated with the effects on amyloid pathology in a mouse model of Alzheimer's disease. 2021 , 159, 105510		1
287	The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. 2021 , 176, 16-33		8
286	Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. 2021 , 16, 1660-1670		7
285	Intranasal insulin. 2021 , 33, e12934		10
284	A Neonatal Mild Defect in Brain Insulin Signaling Predisposes a Subclinical Model of Sporadic Alzheimer's to Develop the Disease. 2021 , 71, 1473-1484		0
283	Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease. 2021 , 4, 193-205		0
282	IGF-1 in Brain Growth and Repair Processes. 2006 , 143-165		1

281	Genomic imprinting and human psychology: cognition, behavior and pathology. 2008 , 626, 71-88	19
280	Metabolic Syndrome as a Risk Factor for Alzheimer Disease. 2013 , 281-341	3
279	The Relationship Between the Continuum of Elevated Adiposity, Hyperinsulinemia, and Type 2 Diabetes and Late-onset Alzheimer's Disease: An Epidemiological Perspective. 2010 , 89-107	2
278	Tau, Diabetes and Insulin. 2019 , 1184, 259-287	1
277	Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases. 2020 , 155, 65-89	5
276	Inflammation: major denominator of obesity, Type 2 diabetes and Alzheimer's disease-like pathology?. 2020 , 134, 547-570	18
275	Insulin receptor activation by proinsulin preserves synapses and vision in retinitis pigmentosa.	1
274	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A β oligomers. 2012 , 122, 1339-53	567
273	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. 2012 , 122, 1316-38	1101
272	The Continuing Evolution of Insulin-like Growth Factor Signaling. 2020 , 9,	6
271	Cognitive dysfunctions in individuals with diabetes mellitus. 2019 , 36, 183-191	24
270	Therapeutic Advantages of Dual Targeting of PPAR- α and PPAR- γ in an Experimental Model of Sporadic Alzheimer's Disease. 2018 , 5,	6
269	The cycad genotoxin MAM modulates brain cellular pathways involved in neurodegenerative disease and cancer in a DNA damage-linked manner. 2011 , 6, e20911	42
268	Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. 2012 , 7, e31124	50
267	Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. 2013 , 8, e58784	75
266	New function of the adaptor protein SH2B1 in brain-derived neurotrophic factor-induced neurite outgrowth. 2013 , 8, e79619	28
265	3 β hydroxysteroid- Δ 24 reductase (DHCR24) protects neuronal cells from apoptotic cell death induced by endoplasmic reticulum (ER) stress. 2014 , 9, e86753	22
264	The impact of anorexigenic peptides in experimental models of Alzheimer's disease pathology. 2019 , 240, R47-R72	10

263	Cognitive Function in Offspring of Mothers with Gestational Diabetes—The Role of Insulin receptor. 2016 , 2,	0
262	Relationship between Alzheimer’s Disease and the Human Microbiome. 147-158	3
261	Role of anti-diabetic drugs as therapeutic agents in Alzheimer’s disease. 2015 , 14, 684-96	11
260	Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients. 2019 , 11, 2724-2734	11
259	Gavage of D-Ribose induces A β like deposits, Tau hyperphosphorylation as well as memory loss and anxiety-like behavior in mice. 2015 , 6, 34128-42	24
258	Diabetes and Alzheimer’s disease - is there a connection?. 2006 , 3, 161-8	13
257	Effects of treadmill exercise on PI3K/AKT/GSK-3 β pathway and tau protein in high-fat diet-fed rats. 2018 , 22, 9-14	13
256	Cross-Interplay between Osmolytes and mTOR in Alzheimer’s Disease Pathogenesis. 2020 , 26, 4699-4711	2
255	Common Pathological Mechanisms and Risk Factors for Alzheimer’s Disease and Type-2 Diabetes: Focus on Inflammation. 2019 , 16, 986-1006	5
254	A Comprehensive Review of Alzheimer’s Association with Related Proteins: Pathological Role and Therapeutic Significance. 2020 , 18, 674-695	9
253	Sleep Disturbances and Cognitive Impairment in the Course of Type 2 Diabetes-A Possible Link. 2021 , 19, 78-91	3
252	Extending Arms of Insulin Resistance from Diabetes to Alzheimer’s Disease: Identification of Potential Therapeutic Targets. 2019 , 18, 172-184	13
251	Cardiovascular dementia - a different perspective. 2010 , 4, 29-52	21
250	At the Crossroads Between Neurodegeneration and Cancer: A Review of Overlapping Biology and Its Implications. 2018 , 11, 77-89	37
249	Intranasal Insulin for Alzheimer’s Disease and Amnesic Mild Cognitive Impairment: Systematic Review and Meta-analysis. 2017 , 27, 161-170	1
248	IGF-IR in neuroprotection and brain tumors. 2009 , 14, 352-75	16
247	Body Fluid pH Balance in Metabolic Health and Possible Benefits of Dietary Alkaline Foods. 2020 , 1, 12	10
246	Dysregulation of Insulin-Linked Metabolic Pathways in Alzheimer’s Disease: Co-Factor Role of Apolipoprotein E 4. 2020 , 4, 479-493	2

245	Managing diabetes in people with dementia: a realist review. 2017 , 21, 1-140	9
244	More Than Mortar: Glia as Architects of Nervous System Development and Disease. 2020 , 8, 611269	9
243	Exploiting Common Aspects of Obesity and Alzheimer's Disease. 2020 , 14, 602360	10
242	Sweet but Bitter: Focus on Fructose Impact on Brain Function in Rodent Models. 2020 , 13,	7
241	Relation Between Obesity, Cognition and Serum Amyloid β Protein Level and Potential Role of Foeniculum vulgare in Reducing Weight and Improving Cognitive Functions. 2017 , 17, 202-212	2
240	Insulin resistance and reduced brain glucose metabolism in the aetiology of Alzheimer's disease. 2016 , 1,	8
239	Prediabetes and Alzheimer's Disease. 2015 , 77, 511-4	11
238	Alzheimer's disease: Unique markers for diagnosis & new treatment modalities. 2015 , 142, 369-82	9
237	The neuroprotective effects of the anti-diabetic drug linagliptin against A β induced neurotoxicity. 2016 , 11, 236-7	17
236	Cognitive deficits and Alzheimer-like neuropathological impairments during adolescence in a rat model of type 2 diabetes mellitus. 2018 , 13, 1995-2004	11
235	The Use of Anti-Diabetic Drugs in Alzheimer's Disease, New Therapeutic Options and Future Perspective. 2018 , 09, 157-174	2
234	Roles of interstitial fluid pH in diabetes mellitus: Glycolysis and mitochondrial function. 2015 , 6, 125-35	54
233	Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal. 2015 , 6, 1223-42	29
232	Mechanisms of brain aging regulation by insulin: implications for neurodegeneration in late-onset Alzheimer's disease. 2011 , 2011, 306905	26
231	Insulin resistance and Alzheimer's disease. 2009 , 42, 475-81	261
230	Neurophysiology of Social Conduct and Impact of Adverse Exposures. 2016 , In Press,	1
229	Lactobacillus plantarum PS128 prevents cognitive dysfunction in Alzheimer's disease mice by modulating propionic acid levels, glycogen synthase kinase 3 beta activity, and gliosis. 2021 , 21, 259	2
228	Disruption of Glucose Metabolism in Aged : A Sporadic Model of Alzheimer's Disease. 2021 , 15, 733007	0

227 Papers of Note. **2005**, 2005, nw10-nw10

226 Psychosocial Issues and Type 2 Diabetes. **2007**, 83-95

225 Protein Misfolding and Disease. 1

224 Status and Potential Therapeutic Importance of n β Fatty Acids in Neurodegenerative Disease. **2009**, 217-260

223 PCOS, Depression, and Alzheimer β Disease. **2009**, 167-179

222 The Role of Insulin Resistance in Age-Related Cognitive Decline and Dementia. **2009**, 433-457

221 Psychiatric Care of the Patient with Diabetes. **2010**, 755-771

220 Diet, Abeta Oligomers and Defective Insulin and Neurotrophic Factor Signaling in Alzheimer β Disease. **2010**, 183-199

219 What Protects Patients with Schizophrenia from Developing Alzheimer Pathology?. **2010**, 45-66

1

218 Neurochemical Aspects of Neurodegenerative Diseases. **2010**, 249-324

217 Neuroimaging of Cardiovascular Disease. **2011**, 215-255

216 Diet and Acne. **2011**, 131-144

215 The Relationship between the IGF System, Nutrition, and Behavior. **2011**, 259-269

214 Protein Misfolding and Disease. 379-400

213 Molecular Aspects of Obesity and Insulin Resistance in Metabolic Syndrome and Neurological Disorders. **2013**, 143-189

212 Demenz und Diabetes mellitus. **2013**, 233-247

211 Modulation of Cognition by Insulin and Aging: Implications for Alzheimer Disease. 115-135

210 Degenerative Brain Diseases and White Matter Injury. **2014**, 281-319

1

209 Insulin Receptor and the Pathophysiology of Alzheimer Disease. 31-50

208 Experimental Approach to Alzheimer Disease. **2014**, 2025-2045

207 Drug Treatments for Alzheimer’s Disease: Hopes and Challenges. **2014**, 1173-1190

206 Cerebral ageing-the role of insulin and insulin-like growth factor signalling: A review. **2014**, 4, 12

205 Effects of Treadmill Exercise on Brain Insulin Signaling, Glucose Metabolism and Tau Hyperphosphorylation in Intracerebroventricular Streptozotocin Induced-Memory Impairment in Rats. **2014**, 23, 99-108

204 Cognitive Impairment in Type 2 Diabetic Patients Treated with Metformin in Comparison with those Taking Glibenclamide. **2014**, 1,

203 Insulin Resistance, Glucose Regulation, Obesity, and Mood. **2016**, 849-871

202 [Diabetes mellitus and the central nervous system]. **2016**, 88, 82-86

2

201 Targeting Nanoparticles to Brain: Impact of N-Methyl d-Aspartate Receptors. **2017**, 199-220

200 A Review and Perspective on Maximizing Brain Plasticity: Priming the Nervous System to Learn. **2017**, 1,

199 Warning SINEs: Alu elements, evolution of the human brain, and the spectrum of neurological disease. 0

198 Medical Family Therapy in Endocrinology. **2018**, 293-319

197 Identification of a simple and novel cut-point based CSF and MRI signature for predicting Alzheimer’s disease progression that reinforces the 2018 NIA-AA research framework. 0

196 Endocrine Disease and Cognition. **2019**, 101-111

195 INSULINO-RESISTENZA E CERVELLO: EVIDENZE MOLECOLARI E NUOVI BIOMARCATORI ALLA BASE DEL LEGAME TRA PATOLOGIE METABOLICHE E NEURODEGENERATIVE. **2019**, 3,

194 Insulin Resistance and Oligodendrocyte/Microvascular Endothelial Cell Dysfunction as Mediators of White Matter Degeneration in Alzheimer’s Disease. 123-145

193 Acute inflammatory events attenuate high-sucrose diet-induced neurodegenerative processes in reproductively normal female wild-type mice. 0

192 Disentangling Mitochondria in Alzheimer’s Disease. **2021**, 22,

2

191	The Effect of Type-2 Diabetes on Cognitive Status and the Role of Anti-diabetes Medications. 2021 , 13, e19176	1
190	Inflammation and insulin resistance in Alzheimer's disease: partners in crime. 2020 , 389-405	0
189	Stem Cell Applications in Metabolic Disorders: Diabetes Mellitus. 2020 , 193-220	
188	Autophagic Dysfunction in Neurodegeneration. 2020 , 25-62	
187	Metabolic Pathways Underlying Neuropsychiatric Disorders and Obesity. 2020 , 415-426	
186	The Interrelationship between Insulin-Like Growth Factor 1, Apolipoprotein E ϵ 4, Lifestyle Factors, and the Aging Body and Brain. 2020 , 7, 265-273	0
185	Mammalian target of rapamycin complexes. 2020 , 325-341	
184	Alzheimer's Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound. 2021 , 22,	3
183	Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2009 , 17, 827-44	4-3 84
182	Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?. 2013 , 3, 197-226	114
181	Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. 2012 , 54, 171-8	30
180	Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. 2009 , 10, 1049-60	91
179	Effects of Tianqijiangtang capsule on survival, self-renewal and differentiation of hippocampal neural stem cells of embryonic rats cultured in high glucose medium. 2019 , 11, 5560-5572	2
178	Diabetic Encephalopathy Affecting Mitochondria and Axonal Transport Proteins. 2020 , 11, 781-793	
177	O-GlcNAcylation Inhibits Endocytosis of Amyloid Precursor Protein by Decreasing Its Localization in Lipid Raft Microdomains.. 2021 , 11,	0
176	Molecular and Biochemical Pathways Encompassing Diabetes Mellitus and Dementia. 2021 ,	2
175	Mechanical Stretching-Induced Traumatic Brain Injury Is Mediated by the Formation of GSK-3 β /Tau Complex to Impair Insulin Signaling Transduction. 2021 , 9,	
174	GSPE pre-treatment protects against long-term cafeteria diet-induced mitochondrial and inflammatory affectations in the hippocampus of rats. 2021 , 1-11	

173	Tau Cleavage Contributes to Cognitive Dysfunction in Strepto-Zotocin-Induced Sporadic Alzheimer's Disease (sAD) Mouse Model. 2021 , 22,	2
172	A Non-Invasive Determination of Ketosis-Induced Elimination of Chronic Daytime Somnolence in a Patient with Late-Stage Dementia (Assessed with Type 3 Diabetes): A Potential Role of Neurogenesis.. 2021 , 5, 827-846	
171	DP189 prevents cognitive dysfunction in D-galactose/Aβ1 induced mouse model of Alzheimer's disease via modulating gut microbiota and PI3K/Akt/GSK-3β signaling pathway. 2021 , 1-13	4
170	Shen-Zhi-Ling oral liquid ameliorates cerebral glucose metabolism disorder in early AD via insulin signal transduction pathway in vivo and in vitro. 2021 , 16, 128	2
169	The potential roles of excitatory-inhibitory imbalances and the repressor element-1 silencing transcription factor in aging and aging-associated diseases. 2021 , 117, 103683	1
168	Ameliorative potential of phloridzin in type 2 diabetes-induced memory deficits in rats. 2021 , 913, 174645	2
167	Can Exercise Training Teach Us How to Treat Alzheimer's disease?. 2022 , 75, 101559	0
166	diabetic Encephalopathy Affecting Mitochondria and Axonal Transport Proteins. 2020 , 11, 781-794	0
165	Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials.. 2022 , 1	2
164	Remembering your A, B, C's: Alzheimer's disease and ABCA1.. 2022 , 12, 995-1018	0
163	Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives.. 2021 , 12, 825816	2
162	New treatment approaches for Alzheimer's disease: Preclinical studies and clinical trials centered on antidiabetic drugs.. 2021 ,	0
161	The Effect of Type 2 Diabetes Mellitus on the Development of Alzheimer's Disease and Its Molecular Mechanism. 2022 , 10, 114-122	
160	Metabolic Features of Brain Function with Relevance to Clinical Features of Alzheimer and Parkinson Diseases.. 2022 , 27,	1
159	A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro.. 2022 , 17, e0261696	0
158	Gut microbiota regulate Alzheimer's disease pathologies and cognitive disorders via PUFA-associated neuroinflammation.. 2022 ,	5
157	Insulin-Like Growth Factor 2: New Roles for a Known Molecule. 2022 , 52, 175-182	0
156	Inhibition of the Akt/PKB Kinase Increases Na ^v 1.6-Mediated Currents and Neuronal Excitability in CA1 Hippocampal Pyramidal Neurons.. 2022 , 23,	0

- 155 Dementia in Diabetes mellitus and Atherosclerosis; Two Interrelated Systemic Diseases.. **2022**, 181, 87-87
- 154 Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer's Disease.. **2022**, 14, 837649 2
- 153 Magnolol attenuates the locomotor impairment, cognitive deficit, and neuroinflammation in Alzheimer's disease mice with brain insulin resistance via up-regulating miR-200c.. **2022**, 13, 531-543 3
- 152 Mechanisms Underlying the Antidiabetic Activities of Polyphenolic Compounds: A Review.. **2021**, 12, 798329 3
- 151 Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease.. **2022**, 1 2
- 150 Type 3 diabetes (T3D) and alzheimer's disease (AD). **2022**, 4, 8-12
- 149 Pathological Human Tau Induces Alterations in the Brain Insulin Signaling Cascade.. **2022**, 16, 805046 0
- 148 Alzheimer's Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms between Alzheimer's Disease and Type 2 Diabetes.. **2022**, 23, 3
- 147 Shared Molecular Mechanisms among Alzheimer's Disease, Neurovascular Unit Dysfunction and Vascular Risk Factors: A Narrative Review.. **2022**, 10, 0
- 146 Sex-Dependent Effects of Stress in Male Rats on Memory and Expression of the Insulin-Like Growth Factor 2 Receptor Gene in the Brains of Offspring. **2022**, 52, 242-250
- 145 Recent Advances in Understanding of Alzheimer's Disease Progression Through Mass Spectrometry-Based Metabolomics. **2022**, 2, 1-17 1
- 144 Impaired insulin signalling and allostatic load in Alzheimer disease.. **2022**, 8
- 143 A Bioinformatics Approach Toward Unravelling the Synaptic Molecular Crosstalk Between Alzheimer's Disease and Diabetes.. *Journal of Alzheimer's Disease*, **2022**, 4-3 2
- 142 Flavonoids: The Innocuous Agents Offering Protection Against Alzheimer's Disease Through Modulation Of Proinflammatory And Apoptotic Pathways.. **2022**, 1
- 141 Multi-Omics Characterization of Type 2 Diabetes Mellitus-Induced Cognitive Impairment in the db/db Mouse Model.. **2022**, 27, 0
- 140 Neuroprotective and Behavioral Benefits of Exogenous Ketone Supplementation-Evoked Ketosis. **2022**, 423-465
- 139 Insulin action in the brain: cell types, circuits, and diseases.. **2022**, 4
- 138 Protective effects of *Aster yomena* (Kitam.) Honda from cognitive dysfunction induced by high-fat diet.. **2022**, e14138

137	Brain Metabolic Alterations in Alzheimer's Disease.. 2022 , 23,	1
136	Migraine, Brain Glucose Metabolism and the "Neuroenergetic" Hypothesis: A Scoping Review.. 2022 , ,	2
135	A Genetic Model of Epilepsy with a Partial Alzheimer's Disease-Like Phenotype and Central Insulin Resistance.. 2022 , 1	0
134	Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives.. 2022 , 6, 177-193	1
133	Comorbidity of Osteoporosis and Alzheimer's Disease: Is 'AKT'-ing on Cellular Glucose Uptake the Missing Link?. 2022 , 101592	0
132	CDK5 inhibition improves glucose uptake in insulin resistant neuronal cells via ERK1/2 pathway. 2021 ,	0
131	Association of metformin use with Alzheimer's disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study.. 2021 , 11, 24069	3
130	Breakdown of the blood-brain barrier: A mediator of increased Alzheimer's risk in patients with metabolic disorders?. 2021 , e13074	2
129	siRNA Mediated GSK3 β Knockdown Targets Insulin Signaling Pathway and Rescues Alzheimer's Disease Pathology: Evidence from and Studies.. 2021 ,	1
128	Insulin receptor activation by proinsulin preserves synapses and vision in retinitis pigmentosa.. 2022 , 13, 383	2
127	Cognitive disorder and dementia in type 2 diabetes mellitus.. 2022 , 13, 319-337	2
126	Image_1.PDF. 2017 ,	
125	Table_1.doc. 2017 ,	
124	Table_2.doc. 2017 ,	
123	Data_Sheet_1.docx. 2019 ,	
122	Image_1.TIF. 2019 ,	
121	Image_2.TIF. 2019 ,	
120	Image_3.TIF. 2019 ,	

119	Image_4.TIF. 2019,	
118	Image_5.TIF. 2019,	
117	Table_1.docx. 2019,	
116	Table_2.DOCX. 2019,	
115	Data_Sheet_1.PDF. 2019,	
114	Image_1.pdf. 2018,	
113	Table_1.DOCX. 2018,	
112	Table_2.docx. 2018,	
111	Data_Sheet_1.pdf. 2019,	
110	DataSheet_1.pdf. 2020,	
109	DataSheet_2.pdf. 2020,	
108	DataSheet_3.pdf. 2020,	
107	Is the Brain Undernourished in Alzheimer's Disease?. 2022, 14,	0
106	Antidiabetic Drugs in the Treatment of Alzheimer's Disease.. 2022, 23,	2
105	Insulin and Memory in Invertebrates.. 2022, 16, 882932	1
104	Induction of Brain Insulin Resistance and Alzheimer's Molecular Changes by Western Diet.. 2022, 23,	1
103	Brain insulin resistance and the therapeutic value of insulin and insulin-sensitizing drugs in Alzheimer's disease neuropathology.. 2022, 1	0
102	High-fat diet-induced diabetes couples to Alzheimer's disease through inflammation-activated C/EBP β /AEP pathway.. 2022,	1

101	Analysis of the Incidence and Risk Factors of Postoperative Delirium in Patients With Degenerative Cervical Myelopathy.. 2022 ,	
100	Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes. 2022 , 13,	1
99	Significance of Brain Glucose Hypometabolism, Altered Insulin Signal Transduction, and Insulin Resistance in Several Neurological Diseases. 2022 , 13,	1
98	α7nAChR activation protects against oxidative stress, neuroinflammation and central insulin resistance in ICV-STZ induced sporadic Alzheimer’s disease.. 2022 , 217, 173402	1
97	Mechanistic insight into inhibition of amyloid fibrillation of human serum albumin by Vildagliptin.. 2022 , 216, 112563	
96	Role of Biliverdin Reductase A in the Regulation of Insulin Signaling in Metabolic and Neurodegenerative Diseases: An Update. 2022 , 23, 5574	2
95	Insulin-Like Growth Factor, Inflammation, and MRI Markers of Alzheimer’s Disease in Predominantly Middle-Aged Adults. <i>Journal of Alzheimer’s Disease</i> , 2022 , 1-12	4-3
94	Diabetes and cognitive decline. 2022 , 37-71	0
93	Interferon beta attenuates recognition memory impairment and improves brain glucose uptake in a rat model of Alzheimer’s disease: Involvement of mitochondrial biogenesis and PI3K pathway. 2022 , 102262	0
92	The Role of Mitochondrial Quality Control in Cognitive Dysfunction in Diabetes.	1
91	Crosstalk Between Autophagy and Nutrigenomics in Neurodegenerative Diseases. 2022 , 175-199	
90	The burden and risks of emerging complications of diabetes mellitus.	4
89	GLP-1-Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. 2022 , 11, 2023	3
88	Insulin Deficiency Increases Sirt2 Level in Streptozotocin-Treated Alzheimer’s Disease-Like Mouse Model: Increased Sirt2 Induces Tau Phosphorylation Through ERK Activation.	
87	Low Serum Insulin-like Growth Factor-I Is Associated with Decline in Hippocampal Volume in Stable Mild Cognitive Impairment but not in Alzheimer’s Disease. <i>Journal of Alzheimer’s Disease</i> , 2022 , 1-10	4-3
86	Insulin and Its Key Role for Mitochondrial Function/Dysfunction and Quality Control: A Shared Link between Dysmetabolism and Neurodegeneration. 2022 , 11, 943	1
85	Role of Hypertension and Hyperlipidemia in the Pathogenesis of Dementia. 2022 , 251-272	
84	Neuroprotective potential of curcuminoids in modulating Alzheimer’s Disease via multiple signaling pathways. 2022 , 29,	

83	Effects of antidiabetic agents on Alzheimer's disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin. 2022 , 17, e0271138	
82	Effect of Selenium Treatment on Central Insulin Sensitivity: A Proteomic Analysis in β Amyloid Precursor Protein/Presenilin-1 Transgenic Mice. 15,	1
81	Metformin inhibits cardiometabolic syndrome associated cognitive deficits in high fat diet rats.	
80	Deletion of serine racemase reverses neuronal insulin signaling inhibition by amyloid- β oligomers.	0
79	Knockdown of CLC-3 may improve cognitive impairment caused by diabetic encephalopathy. 2022 , 190, 109970	0
78	Icariin ameliorates memory deficits through regulating brain insulin signaling and glucose transporters in 3Tg-AD mice. 2023 , 18, 183	1
77	Insulin Resistance and Cognitive Impairment: Evidence From Neuroimaging.	0
76	Biological and Disease Hallmarks of Alzheimer's Disease Defined by Alzheimer's Disease Genes.	
75	Reduced Hippocampal and Anterior Cingulate Expression of Antioxidant Enzymes and Membrane Progesterone Receptors in Alzheimer's Disease with Depression. <i>Journal of Alzheimer's Disease</i> , 2022 , 1-13	4-3
74	Trends in insulin resistance: insights into mechanisms and therapeutic strategy. 2022 , 7,	10
73	Hallmarks of Neurodegenerative Disease: A Systems Pharmacology Perspective.	0
72	Inside the diabetic brain: Insulin resistance and molecular mechanism associated with cognitive impairment and its possible therapeutic strategies. 2022 , 182, 106358	3
71	Sex Differences in Hypothalamic Changes and the Metabolic Response of TgAPP Mice to a High Fat Diet. 16,	0
70	Saffron as a promising therapy for diabetes and Alzheimer's disease: mechanistic insights.	
69	The Role of Obesity and Diabetes in Dementia. 2022 , 23, 9267	2
68	Targeting the liver in dementia and cognitive impairment: Dietary macronutrients and diabetic therapeutics. 2022 , 190, 114537	0
67	AdipoRon induces AMPK activation and ameliorates Alzheimer's like pathologies and associated cognitive impairment in APP/PS1 mice. 2022 , 174, 105876	1
66	Review - Combinatory approaches targeting cognitive impairments and memory enhancement. 2022 , 23,	0

65	The neuroprotective effects of glucagon-like peptide 1 in Alzheimer β and Parkinson β disease: An in-depth review. 16,	2
64	Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols. 2022 , 14, 1870	1
63	Differential regulation of insulin signaling by monomeric and oligomeric amyloid beta-peptide.	0
62	Multi-nutrient interventions and cognitive ageing: are we barking up the right tree?. 1-33	0
61	From Small Peptides to Large Proteins against Alzheimer β Disease. 2022 , 12, 1344	3
60	Oxidative Stress Kinase Activation and Impaired Insulin Receptor Signaling Precede Overt Alzheimer β Disease Neuropathology. 2022 , 1-17	0
59	MicroRNA -140-5p inhibitor attenuates memory impairment induced by amyloid- β oligomer in vivo possibly through Pin1 regulation.	0
58	A Pathophysiological Intersection of Diabetes and Alzheimer β Disease. 2022 , 23, 11562	1
57	Streptozotocin-Induced Alzheimer's disease Investigation by One-dimensional Plasmonic Grating Chip.	0
56	Cerebrovascular insulin receptors are defective in Alzheimer β disease.	1
55	Does Oxidative DNA Damage Trigger Histotoxic Hypoxia via PARP1/AMP-Driven Mitochondrial ADP Depletion-Induced ATP Synthase Inhibition in Alzheimer β Disease?. 2022 ,	1
54	SYK coordinates neuroprotective microglial responses in neurodegenerative disease. 2022 , 185, 4135-4152.e22	1
53	Potential mechanisms to modify impaired glucose metabolism in neurodegenerative disorders. 0271678X2211850	1
52	Brain insulin resistance and cognitive function: influence of exercise.	0
51	Insulin stimulates atypical protein kinase C-mediated phosphorylation of the neuronal adaptor FE65 to potentiate neurite outgrowth by activating ARF6-Rac1 signaling. 2022 , 36,	0
50	Neuroprotective Action of Coumarin Derivatives through Activation of TRKB-CREB-BDNF Pathway and Reduction of Caspase Activity in Neuronal Cells Expressing Pro-Aggregated Tau Protein. 2022 , 23, 12734	2
49	Hindbrain insulin controls feeding behavior. 2022 , 66, 101614	1
48	Branched-Chain Amino Acids Are Linked with Alzheimer β Disease-Related Pathology and Cognitive Deficits. 2022 , 11, 3523	1

47	The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease. 13,	0
46	Biological and disease hallmarks of Alzheimer's disease defined by Alzheimer's disease genes. 14,	2
45	Association of the triglyceride-glucose index with risk of Alzheimer's disease: a prospective cohort study.	0
44	Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer's disease. 2022, 17,	0
43	Effects of distinct n-6 to n-3 polyunsaturated fatty acid ratios on insulin resistant and AD-like phenotypes in high-fat diets-fed APP/PS1 mice. 2022, 112207	0
42	Sporadic Alzheimer's disease animal model using streptozotocin and APP/PS1 mice. 2023, 17-30	0
41	The immune-stress/endocrine-redox-metabolic nature of psychosis etiology; focus on the intersystemic pathways interactions. 2023, 794, 137011	0
40	Efficacy of Glucose Metabolism-Related Indexes on the Risk and Severity of Alzheimer's Disease: A Meta-Analysis. 2022, 1-16	0
39	Brain Insulin Resistance, Nitric Oxide and Alzheimer's Disease Pathology. 2022, 238-259	0
38	BACE2: A Promising Neuroprotective Candidate for Alzheimer's Disease. 2022, 1-13	0
37	Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.	0
36	The Role of Caspases in Alzheimer's Disease: Pathophysiology Implications and Pharmacologic Modulation. 2022, 1-20	1
35	The Strategies for Treating Alzheimer's Disease—Insulin Signaling May Be a Feasible Target. 2022, 44, 6172-6188	0
34	The Role of Impaired Receptor Trafficking in Mediating the Pathological Effects of ApoE4 in Alzheimer Disease.	0
33	Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts.	1
32	High-Intense Interval Training Prevents Cognitive Impairment And Increases The Expression Of Muscle Genes Fndc5 And Pparg1a In A Rat Model Of Alzheimer's Disease. 2022, 20,	0
31	Streptozotocin-induced Alzheimer's disease investigation by one-dimensional plasmonic grating chip. 2022, 12,	0
30	Type 2 Diabetes Mellitus and Alzheimer's Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets. 2022, 23, 15287	2

29	Ameliorative effects of bromelain on aluminum-induced Alzheimer's disease in rats through modulation of TXNIP pathway. 2022 ,	2
28	The identities of insulin signaling pathway are affected by overexpression of Tau and its phosphorylation form. 14,	0
27	Intranasal Administration of KYCCSRK Peptide Rescues Brain Insulin Signaling Activation and Reduces Alzheimer's Disease-like Neuropathology in a Mouse Model for Down Syndrome. 2023 , 12, 111	1
26	Experimental Approach to Alzheimer's Disease with Emphasis on Insulin Resistance in the Brain. 2022 , 1657-1708	0
25	Mediterranean Diet, Ketogenic Diet or MIND Diet for Aging Populations with Cognitive Decline: A Systematic Review. 2023 , 13, 173	0
24	Alteration of Metabolic Profile During the Progression of Alzheimer's Disease.	0
23	PP2C α Aggravates neuronal insulin resistance leading to AD-like phenotype in vitro. 2023 , 644, 49-54	1
22	Cell non-autonomous regulation of cerebrovascular aging processes by the somatotrophic axis. 14,	0
21	Genetic Factors Implicated in the Investigation of Possible Connections between Alzheimer's Disease and Primary Open Angle Glaucoma. 2023 , 14, 338	0
20	The Expression of Insulin in the Central Nervous System: What Have We Learned So Far?. 2023 , 24, 6586	0
19	Metabolic defects shared by Alzheimer's disease and diabetes: A focus on mitochondria. 2023 , 79, 102694	1
18	Amygdala activity and amygdala-hippocampus connectivity: Metabolic diseases, dementia, and neuropsychiatric issues. 2023 , 162, 114647	0
17	How Can Insulin Resistance Cause Alzheimer's Disease?. 2023 , 24, 3506	1
16	Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration. 2023 , 43, 077-088	0
15	Clinical antidiabetic medication used in Alzheimer's disease: From basic discovery to therapeutics development. 15,	0
14	The Alzheimer's Disease Mitochondrial Cascade Hypothesis: A Current Overview. 2023 , 92, 751-768	0
13	Using Optogenetics to Model Cellular Effects of Alzheimer's Disease. 2023 , 24, 4300	0
12	Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: A Focus on Insulin Resistance. 2023 , 24, 4354	0

- 11 The Effects of Momordica charantia on Type 2 Diabetes Mellitus and Alzheimer’s Disease. **2023**, 24, 4643 ○
- 10 Modifying Dietary Protein Impacts mTOR Signaling and Brain Deposition of Amyloid β in a Knock-In Mouse Model of Alzheimer Disease. **2023**, ○
- 9 Increased Expression of Autophagy-Related Genes in Alzheimer’s Disease/Type 2 Diabetes Mellitus Comorbidity Models in Cells. **2023**, 20, 4540 ○
- 8 Actions and Consequences of Insulin in the Striatum. **2023**, 13, 518 ○
- 7 Natural bioactive compounds in Alzheimer’s disease: From the perspective of type 3 diabetes mellitus. 15, ○
- 6 The Association Between Cardiovascular Disease and Dementia: A Review of Trends in Epidemiology, Risk Factors, Pathophysiologic Mechanisms, and Clinical Implications. Publish Ahead of Print, ○
- 5 Insulin-like growth factor-2 is a promising candidate for the treatment and prevention of Alzheimer’s disease. ○
- 4 IGF2 in memory, neurodevelopmental disorders, and neurodegenerative diseases. **2023**, ○
- 3 Geroprotective interventions in the 3xTg mouse model of Alzheimer’s disease. ○
- 2 Insulin and Disorders of Behavioural Flexibility. **2023**, 105169 ○
- 1 Metabolic Overlap between Alzheimer’s Disease and Metabolic Syndrome Identifies the PVRL2 Gene as a New Modulator of Diabetic Dyslipidemia. **2023**, 24, 7415 ○